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Abstract
Fetal growth restriction (FGR) is associated with decreased nutrient availability
and reduced insulin-like growth factor (IGF)-I bioavailability via increased IGF binding
protein (IGFBP)-1 phosphorylation. While protein kinase C (PKC) is implicated in
IGFBP-1 hyperphosphorylation in nutrient deprivation, the mechanisms remain unclear. I
hypothesized that the interaction of PKCα with protein kinase CK2β and activation of
PKCα under leucine deprivation (L0) mediate fetal hepatic IGFBP-1
hyperphosphorylation. Parallel Reaction Monitoring Mass Spectrometry (PRM-MS)
followed by PKCα knockdown demonstrated the PKCα isoform interacts with IGFBP-1
and CK2β under L0. Pharmacological PKCα activation with phorbol 12-myristate 13acetate (PMA) increased whereas inhibition with bisindolylmaleimide II (Bis II)
decreased IGFBP-1 phosphorylation (Ser101/119/169, Ser98+101 and Ser169+174),
respectively. Furthermore, PMA mimicked L0-induced PKCα translocation and IGFBP-1
expression. PKCα expression was increased in baboon fetal liver in FGR, providing
biological relevance in vivo. In summary, I report a novel nutrient-sensitive mechanism
for PKCα in mediating IGFBP-1 hyperphosphorylation in FGR.

A version of this thesis has been accepted for publication with permission for reproduction
requested from Elsevier.
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Summary for Lay Audience
Fetal growth restriction (FGR) affects approximately 5-10% of all pregnancies
and occurs when the fetus fails to reach its growth potential in the uterus. The most
common cause of FGR is placental insufficiency, a pathological condition where the
placenta fails to adequately supply oxygen and nutrients to the developing fetus. FGR is
the second most common cause of perinatal mortality and is responsible for 30% of
stillbirths. Additionally, FGR may negatively affect physical and neurological
development of the infant resulting in increased risk of metabolic, cardiac and
neurological disorders which may not resolve in adulthood.
Fetal growth is primarily mediated by fetal liver secreted insulin-like growth
factor I (IGF-I), a peptide hormone which is bound by insulin-like growth factor binding
proteins (IGFBPs) which extends the half-life of IGF-I in circulation and mediates its
functions. IGFBP-1 is additionally secreted by the fetal liver and is predominantly
expressed during pregnancy where it serves its primary role of binding to and inhibiting
IGF-I regulated fetal growth. Phosphorylation of IGFBP-1 increases its binding affinity
for IGF-I resulting in greater inhibition of IGF-I mediated actions. In FGR, IGFBP-1
phosphorylation is increased and IGF-I bioavailability is reduced which are associated
with decreased fetal nutrient provision. We have previously utilized the hepatoblastoma
derived HepG2 cell line deprived of leucine as a model for the nutritionally deprived fetal
liver to induce IGFBP-1 phosphorylation. However, the roles of the kinases which
mediate the phosphorylation of IGFBP-1 in this model have not yet been elucidated.
In this study, we hypothesized that leucine deprivation (L0) activates protein
kinase C (PKC) in a nutrient sensitive manner and induces its interaction with the
putative IGFBP-1 kinase, protein kinase CK2 which results in increased IGFBP-1
phosphorylation. I found that PKC interacts with IGFBP-1 and CK2 in L0 and that PKC
is activated in L0. Additionally, I demonstrate that PKC mediates IGFBP-1
phosphorylation in L0. To establish translational relevance, I further demonstrated global
maternal nutrient restriction induces PKC expression within the fetal liver which is
associated with increased IGFBP-1 phosphorylation.
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Background Information

1.1 Fetal Growth Restriction
Fetal Growth Restriction (FGR) also known as Intrauterine Growth Restriction
(IUGR) has been described as a reduction of fetal growth from its expected biological
potential, however, this description often converges with small for gestational age (SGA)
fetuses as both are habitually defined with estimated fetal weight below the 10th
percentile for gestational age 1. This definition, however, does not discern between
pathological FGR or healthy constitutionally small fetuses and distinguishing these
processes is difficult. Epidemiological studies demonstrated a decline in neonatal deaths
and newborn morbidities with increasing gestational age, suggestive that SGA babies
delivered at appropriate term are likely to be constitutionally small and not pathologically
FGR2. FGR demonstrates an increased risk for adverse pre- and postnatal events,
including adult morbidities including metabolic and cardiac disorders 1,3,4. FGR is a
pathological consequence of maternal, fetal, and/or placental factors contributing to the
restricted growth potential of an individual and as of yet, no succinct definition exists.
The etiology of FGR is expansive and complicated with risk factors encompassing but
not limited to fetal genetics 5, perinatal infection 6,7, interventional therapeutics 8,
environmental pollution 9,10 and maternal health 11,12. FGR affects 5-10% of all
pregnancies and is associated with higher rates of neonatal mortality and morbidities 13,14.
Currently, FGR screening methods are lacking. Prenatal detection of FGR is difficult and
is primarily based on maternal risk factors and clinical assessments of maternal features
(e.g. serum biochemistry and uterine artery blood flow) in conjunction with sonographic
screening of the fetus 15.

1.1.1

Regulation of Fetal Growth
Fetal growth is a complex and dynamic process regulated by various maternal,

placental and fetal factors of both genetic and environmental origin in multidirectional
interactions. The placenta is the site of exchange between mother and fetus and regulates
fetal growth via growth-regulating hormones such as the insulin-like growth factors
1

(IGFs). Fetal provision can be regulated by fetal and placental endocrine signals to
increase transport of maternal nutrients by growth of the placenta and activation of
transport systems. Poor fetal growth is inundated with consequences both in prenatal and
postnatal life in the form of increased mortality and morbidity.

1.1.2

Maternal and Placental Contributions in Fetal Growth
Primary maternal contributions to fetal growth encompass maternal genetics, the

uterine environment and maternal nutritional intake 12. Maternal uterine capacity is a key
determinant of fetal size and is correlated with genetic maternal height and represents a
potential capacity for fetal growth 16. Furthermore, uterine blood flow must meet
metabolic demands of the growing uterus, placenta, and fetus 17. Over the course of
pregnancy, total maternal blood volume 18 and cardiac output increases by ~40% 19 while
uterine artery flow rate increases >3-fold 17.

1.1.2.1

Maternal Nutrient Intake and Fetal Growth

Effects on the placenta
The placenta is composed of both maternal and fetal tissues and serves as the site
of exchange between mother and fetus and is a metabolically active organ sustained by
uterine circulation, of which, the placenta extracts 40-60% of total glucose and oxygen 20.
Nutrient transfer between placenta and fetus occurs via passive diffusion, facilitated
diffusion, active transport, endocytosis and exocytosis 12. As fetal growth rate increases
over the course of gestation, placental growth and fetoplacental transfer also increase to
meet increasing fetal nutritional demands 21,22. Maternal undernutrition results in
reduction of placental weight and reduced placental function 23–25. Nutritional deprivation
that results in human FGR is associated with decreased vasculogenesis, angiogenesis and
generates deficient placentas with reduced surface area for nutrient exchange 26–28.
Causative FGR factors resultant of maternal nutrient deficiency include downregulated
placental nutrient transport prior to the onset of FGR 29,30.
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Effects on the fetus
Maternal nutrient intake is a significant factor in normal fetal growth. During the
second and third trimesters, increased caloric intake is necessary to accommodate
fetoplacental growth 31. Low protein intake during late pregnancy is correlated to reduced
birth weight 32. Furthermore, a Cochrane systematic review found that balanced proteinenergy supplementation resulted in a 30% reduced risk of SGA neonates 33. Overall, an
assessment of complete maternal dietary intake (total energy, protein and carbohydrate)
indicated that protein intake is positively correlated with birth weight and ponderal index
(an assessment of birth weight and length) whilst carbohydrate overconsumption in early
pregnancy is negatively correlated with ponderal index, suggesting that sufficient protein
intake is necessary for symmetrical growth 34. Ultimately, the major non-genetic factors
determining fetal size is referred to as maternal constraint – a plethora of maternal and
uteroplacental factors, including the uterine environment in limiting support of fetal
growth by mediating hormonal signals, nutrient availability and metabolism which are
dependent upon maternal nutrient intake 11.
Effects on the fetal liver
Nutritional insult during gestation results in organ dysfunction and abnormal
development 35. Maternal undernutrition during fetal development commonly results in
decreased liver weight and liver fibrosis 36,37. Reduced liver functions, such as impaired
cholinesterase activity, antioxidant capacity, glucose metabolism and lipid metabolism
also occur due to reduced maternal intake 36,38. Although many of the metabolic and
digestive functions of the liver are not critical during gestation, the liver remains sensitive
to the levels of metabolic substrates and alters its protein synthesis accordingly 39,40. The
liver is also particularly significant as the primary secretor of plasma proteins and
therefore changes in its protein secretion affects the fetal body 41,42.

1.2

Placental Insufficiency in FGR

The placenta supplies the fetus oxygen and nutrient rich blood through the
umbilical vein directly to the fetal liver and to the fetal heart via the ductus venosus
(Figure 1) 43. Pathological placental dysfunction related FGR occurs primarily due to
3

deficient maternal uterine spiral remodeling, leading to decreased fetoplacental oxygen
and nutrient transfer 44. In these cases, placental and fetal adaptations are necessary to
accommodate for deficient nutrient availability 45–49. The placenta serves to integrate
maternal metabolic hormones such as low circulating insulin, IGF-1, leptin and elevated
cortisol 30,50 to alter expression and/or activity of nutrient transporters supplying fetal
provision 51–53. The fetal liver integrates maternal nutrient supply and physiologically
responds by mediating umbilical blood flow from the liver to fetal cardiac circulation via
ductus venosus shunting resulting in decreased liver size and function 36–38,54,55. As such,
maternal undernutrition may induce placental insufficiency, the principal cause of FGR
and the pathobiological consequence is mediated by placental hormones which regulate
fetoplacental nutrient transfer and ductus venosus shunting of maternal blood supply to
maintain fetal cardiac function at the cost of fetal liver development and function 38,55–58.

Figure 1. Anatomic scheme of placental blood supply to fetal liver through the
umbilical cord with ductus venosus shunting.
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1.2.1

Inadequate amino acid transfer in FGR due to placental
insufficiency
The importance of adequate amino acid supply is facilitated by the fetal liver,

which mediates cardiac circulation of amino acids to regulate fetal development via the
ductus venosus 28,56. Fetoplacental amino acid transfer is essential for fetal growth 51.
Fetal amino acid plasma concentration remains mostly constant over the course of
pregnancy and is significantly higher than maternal concentration 59–62. Fetal amino acids
are supplied by the placenta through the umbilical cord, however, fetal amino acid
concentration is determined by placental amino acid transfer 63,64. In growth restricted
fetuses, placental amino acid transfer is reduced 65 and amino acid concentration is
significantly decreased in the umbilical artery and vein 66–68 with specifically decreased
concentrations of essential branched chain amino acids (BCAAs) (valine, leucine and
isoleucine) 62. In animal models, decreased amino acid transfer occurs prior to the onset
of FGR, emphasizing a causal role 29. Several distinct systems of placental amino acid
transporters have been described 69. These transporters function within the
syncytiotrophoblast of the human placenta at the microvillous (MVM; maternal facing)
and basal (BM; fetal facing) membranes and transport amino acids against their
concentration gradient 70. Inadequate transplacental amino acid transfer leads to increased
maternal amino acid concentration and decreased fetal amino acid concentration observed
in FGR pregnancies 68,71
Within FGR, significant reduction in transplacental flux and fetal turnover ratios
of essential amino acids have been demonstrated 72–74. Reduction in fetal amino acid
concentrations in FGR cases may be attributed to the downregulation of expression
and/or activity of specific transporters 29,73. Na+ dependent System A transporter which
mediates small and neutral amino acid uptake has been demonstrated to exhibit decreased
transport activity in FGR cases with respect to FGR severity 75–77. Na+ independent
System L mediates transport of neutral amino acids with bulkier side chains such as
leucine 69. Although System L expression and activity at both the MVM and BM is not
directly downregulated in early gestation FGR models 30, System L transport is
5

dependent upon exchange of non-essential amino acids supplied by System A for
essential amino acids such as leucine 78 which may result in impaired System L transport
and reduced BCAA concentration within fetal circulation 30,62. In later gestation FGR
models, cumulative effects of downregulated System A transport and reduced small,
neutral amino acid concentrations results in a marked 84% reduction in System L
transport 58.
Fetal growth is intimately linked to transplacental amino acid transport in both
placental insufficiency induced FGR and in fetal overgrowth where transport is
downregulated and upregulated, respectively 73,75,79–82. Low leucine availability, in
particular, has been implicated in FGR onset. Dichorionic average for gestational age
(AGA) and FGR twin studies demonstrated significant reductions in BCAA
concentrations in fetal plasma and in particular, a highly significant decrease in fetomaternal leucine ratio 83. Likewise, significant reduction of leucine within fetal
circulation has been identified in non-human primate models of FGR 49. Teodoro et al.
(2012) explored the distinct effects of leucine separate from isoleucine and valine in
attenuating maternal protein deficiency induced growth restriction and concluded that
leucine alone, apart from other BCAAs, is necessary for normal growth and organ mass
in rat fetuses and supplementation of leucine is capable of restoring normal fetal growth
84

.

1.2.2

Fetal Responses to Placental Insufficiency and Reduced
Amino Acid Transport
Persistent placental insufficiency resulting in a declining nutrient deficit leads to

an inability to maintain both fetal oxidative metabolism and placental function 85. At this
stage, concurrent down-regulation of active placental transport such as amino acid
transporters and increasing fetal demands result in more widespread metabolic responses
48,86,87

. At advanced stages of malnutrition, fetal metabolic responses cumulate to the

breakdown of endogenous muscle protein, failure to accumulate adipose stores and
premature activation of hepatic gluconeogenesis 85,88. Accordant to the degree and
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severity of FGR, thyroid function at all levels is impaired 89,90 while corticotrophin
releasing hormone and cortisol levels are significantly elevated 91,92.
Response of the Fetal Liver
Reduction in amino acid availability due to maternal undernutrition results in
several biochemical fetal liver consequences. The proteomic liver profile of maternal
nutrient restricted fetal liver demonstrates induction of cholesterol biosynthesis,
inhibition of fatty acid oxidation and thyroid hormone metabolism 40. Further metabolic
effects include increases in BCAA oxidation and gluconeogenic capacity 39,93. Reduction
of general cell growth and proliferation kinase mechanistic target of rapamycin (mTOR)
activity and increased amino acid response (AAR) pathway signaling is additionally
observed in the fetal liver of maternal nutrient restriction 94. Liver growth hormone (GH)
and hepatocyte growth factor are induced in maternal nutrient restriction 95. Additionally,
the principal endocrine growth axis involving the metabolic and mitogenic peptides
insulin, IGF-I and IGF-II is immediately downregulated upon critical placental
insufficiency 96. Fetal liver expression of fetal hepatic growth peptides IGF-I and IGF-II
are reduced concomitant with the increase of their half-life extending carrier proteins 97.
Additionally, pro-apoptotic factors are upregulated 95,97.

1.3

The Insulin-like Growth Factor (IGF) Axis and

Fetal Growth
The most important determinant of fetal growth is the IGF system 98. The IGFs
compose of two ligands, IGF-I and IGF-II and exist as single polypeptide chains which
share similar amino acid sequence homology with proinsulin, however, primarily govern
mitogenic roles instead of metabolic roles 99,100. Baker et al. utilized embryonic null
mutations in elegant mice studies to demonstrate the importance of the IGF system in
fetal growth 101. Deletion of Igf1 or Igf2 results in similar level of fetal growth restriction
(60% of normal birth weight). In Igf1 and Igf2 knockouts, growth was further reduced
(30% of normal birth weight) indicating both IGFs are critical in fetal growth and likely
serve distinct roles. Deletion of the type 1 IGF receptor (IGF-1R) gene Igf1r alone with
Igf1 results in more severe growth restriction (45% of normal birth weight) than deletion
7

of Igf1 or Igf2 alone, suggesting that IGF-1R mediates growth via both IGF-I and IGF-II.
Dual Igf1r and Igf2 deletions resulted 30% of normal birth weight, further suggesting that
the role of IGF-II is critically different than those of IGF-I. Although Igf1 or Igf2
deletions both result in similar fetal growth restricted phenotypes, a separate study
observed placental hypoplasia only in Igf2 deletions, suggesting that growth mediation in
the fetus is highly dependent on IGF-I and that IGF-II has a function in placental
development distinct from IGF-I 102.
Both IGFs are expressed in fetal tissues from pre-implantation to the final stages
of tissue maturation prior to birth and are thought to primarily act in autocrine and
paracrine fashion, with endocrine action occurring in the latter half of gestation 103–105.
Relatively, IGF-II concentrations are consistently higher than IGF-I concentrations within
human fetal circulation (3-10 fold) 106. Fetal serum concentrations of IGF-I and IGF-II
increase with progressing gestation, however, the greatest rise is observed in IGF-I in late
gestation 107–109. IGF-I concentrations increase dramatically in the second and third
trimesters as developmental changes in IGF expression become tissue specific and fetal
liver dependent 109–111.
Initial findings regarding fetal plasma concentrations and Igf2 mRNA abundance
in fetal tissues lead to the hypothesis that IGF-II was the primary mediator of fetal growth
105,106,112,113

. However, Baker et al.’s studies on Igf1 and Igf2 null mutations in mouse

embryos asserted that both IGF-I and IGF-II were necessary for normal fetal growth 101.
While IGF-II is more abundant than IGF-I during fetogenesis, only IGF-I plasma
concentrations were found to be positively correlated with fetal size, length and
birthweight 106,107,114,115. IGF-II instead has been established as the primary growth factor
mediating embryonic and placental development 116–119. Additionally, two studies by
DeChiara et al.,(1990, 1991) demonstrated that IGF-II while important for growth, is not
necessary for producing viable offspring without severe defects unlike IGF-I 102,120.
During the exponential growth phase of the third trimester, IGF-I levels rise dramatically
as the somatotropic axis begins to influence IGF-I production in the fetal liver 110,119,121.
Fetal IGF-I concentration increases exponentially from a mean of 15 ug/L to 70 ug/L
while fetal IGF-II concentration rises linearly from a mean of 600 ug/L to 900 ug /L over
8

the course of 15 weeks to 40 weeks of gestation 109. IGF-I as opposed to IGF-II, is the
primary mediator of fetal growth in later gestation 104.
Maternal IGFs further affect fetal growth 122. IGF-I and IGF-II are produced in
several maternal tissues such as skeletal muscle, liver, adipose tissue and uterus 123–126.
Additionally, the placenta synthesizes substantial amounts of IGF-II but not IGF-I 127.
Maternal IGF-I consistently rises during the course of pregnancy while IGF-II
concentrations remain relatively constant 128. However, maternal IGFs do not cross the
placental barrier in significant quantities 129, thus, the regulation of fetal growth by
maternal IGFs are due to their effects on inducing placental development and modulating
maternal metabolism and nutritional partitioning to sustain favourable maternal-fetal
provision 122.

1.3.1

The IGF receptors and their functions
The IGFs are primarily mitogenic proteins that are highly conserved and

structurally homologous to insulin 99,100. Although structurally similar, the functions of
the IGFs and insulin are divergent with the IGFs primarily serving mitogenic functions
modulating cell growth and proliferation 130,131 and insulin primarily mediating glucose
transport and the biosynthesis of glycogen and fat 132. The IGFs exert their actions via
their receptors. The type 2 IGF receptor binds with IGF-II with high affinity and serves
primarily to clear IGF-II from circulation 133. IGF-1R in contrast, is a tyrosine kinase with
significant homology to the insulin receptor (IR) 134 and mediates the growth-promoting
actions of both IGF-I and IGF-II 135.
The mature, functional form of IGF-1R has a membrane spanning
heterotetrameric (α2β2) structure formed from pre-formed dimers (αβ), all linked by
disulfide bridges 131. The αβ pro-receptor is synthesized as a single chain and processed
by proteolysis and glycosylation 136,137. Ligand binding is mediated by the N-terminal
extracellular α-subunits which are additionally conserved in the insulin receptor (IR)
134,138

. The α-subunit contains two homologous domains (L1 and L2) 139 separated by a

cysteine-rich domain that mediates ligand binding 140. The β-subunit contains
extracellular, plasma membrane spanning and intracellular domains 141. The intracellular
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domain of the β-subunit is subdivided into three domains: a juxtamembrane domain, a
tyrosine kinase domain and a C-terminal domain 142. The juxtamembrane domain may
mediate receptor internalization 143,144. The tyrosine kinase domain contains a
pseudosubstrate activation loop that contains critical Tyr residues 1131, 1135 and 1136
(with Tyr1131 occluding ATP binding) which are trans-phosphorylated by the dimeric
subunit partner upon ligand binding and results in stabilization and catalytic competence
of the tyrosine kinase domain 145. After trans-phosphorylation of IGF-1Rβ Tyr residues,
signal transduction molecules and adaptor proteins such as the Insulin Receptor
Substrates (IRSs) and Shc proteins are able to bind to sites outside of the kinase domain
and activate downstream signaling pathways 130.

1.3.2

Insulin-like growth factor binding proteins (IGFBPs)
Six IGFBPs (1-6) bind the IGFs with high affinity within the nanomolar range

146,147

. These proteins share an overall protein sequence homology of 50% and share

conserved cysteine residues in the N and C-terminal domains 148. The IGFs are primarily
bound to IGFBPs within circulation thus prolonging the half-life of circulating IGFs 149,
which is typically just 10-12 minutes 150. IGFBP-3 is the most abundant IGFBP in
circulation and predominantly forms a ~150 kDa ternary complex with the IGFs and an
acid-labile subunit 151. 75% of circulating IGFs are bound in this ~150 kDa ternary
complex which prolongs the half-life of the IGFs to ~15 h 150. No other IGFBP has such a
stabilizing effect on prolonging the half-life of the IGFs 151. The IGFBPs have several
proposed functions with respect to both IGF-dependent and IGF-independent actions
130,152

. IGF-dependent functions include acting as carrier proteins, providing tissue

specificity and modulating interactions between the IGFs and their receptors 146. IGFBP-1
and IGFBP-2 contain Arg-Gly-Asp (RGD sequence) which serves as an integrin receptor
sequence which binds to α5β1 integrin receptor which mediates cell migration 148,153.
IGFBP-3 has IGF-independent inhibitory actions on cell growth and DNA synthesis 154.
IGFBP-5 has been demonstrated to have some IGF-independent mitogenic properties 155.
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1.3.3

IGFBP structure
The IGFBPs range from ~24 to 50 kDa and are conserved structurally, sharing

similarities amongst their structured cysteine-rich, disulfide linked N- and C-terminal
domains which contribute to IGF binding which are linked by a less structured and less
conserved linker domain 147. Both the N- and C-terminal domains of the IGFBPs share
conserved IGF binding determinants, which are both necessary for high-affinity IGF
binding 156,157. Structural studies 158,159 determined key Val and Leu residues within the
conserved N-domain that form a deep binding cleft which allows for IGF binding
contributes to 1000-fold greater binding affinity than mutagenized IGFBP analogues 160–
162

. The lesser conserved and predominantly unstructured linker region contains sites for

post-translational modification and proteolysis, while additionally contributing to IGFbinding 147. Isolated N- and C-terminal domains, without the linker region, demonstrate
up to a 100-fold loss in binding affinity 163,164. The linker regions of IGFBP-1, -3 and -5
permit phosphorylation 165.

Figure 2. Schematic of IGFBP-1. Mature IGFBP-1 contains 234 residues and contains
an N-terminal region, central linker region and C-terminal region. The N- and C-terminal
domains are structured by disulfide bonds which are conserved amongst IGFBPs. The
α5β1 integrin receptor binding RGD motif is located in the C-terminal. Phosphorylation
sites are located within the linker region and C-terminal region.
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1.3.4

IGFBP-1 regulates IGF-I bioavailability during pregnancy
During pregnancy, there are several sources of IGFBP-1 localized to different

compartments. Fetal circulating IGFBP-1 is primarily secreted by the fetal liver 166 and is
a potent inhibitor of the mitogenic actions of the IGFs both in vitro 167 and in vivo 168,169
thereby mediating fetal IGF-I bioavailability and thus directly regulating fetal growth 104.
An inverse correlation of fetal serum IGFBP-1 levels and birthweight has been observed,
with marked increased levels of fetal IGFBP-1 in FGR 115,170. Circulating IGFBP-1 is
greatest during pregnancy 171 and maternal serum concentrations rise 25-fold over the
course of gestation 172. Maternal IGFBP-1 is primarily secreted from the endometrium by
decidual cells into the placenta where it inhibits trophoblast invasion 122.
IGFBP-1 expression is largely regulated by the fetal environment 173,174. A nongrowth inducive environment such as low oxygen tension and low nutrient availability
results in increased IGFBP-1 expression in both maternal and fetal compartments, which
results in aberrant placental development and reduced fetal IGF-I bioavailability 12. Fetal
hepatic expression and circulating levels of IGFBP-1 are increased in FGR 175,176. Fetal
liver expression of IGFBP-1 has been extensively investigated in models. The expression
and secretion of IGFBP-1 by the fetal liver in non-growth inducive environments are
attributed to mTOR inhibition and the AAR upregulation 94,177–180. In this way,
nutritionally induced alterations in fetal liver IGFBP-1 expression entertains the duality
of maternal constraint 11 and fetal programming 121 establishing IGFBP-1 as the
regulatory protein which attenuates fetal growth if the environment is not conducive to
sustaining the exponential growth phase during the third trimester.

1.3.5

IGFBP-1 phosphorylation and the regulation of IGF-I
bioavailability
Phosphorylation of IGFBP-1 potently enhances its affinity for IGF-I 181,182 as well

as its capacity to inhibit IGF-I dependent actions 183 such as cell proliferation, amino acid
transport 184 and DNA synthesis 185,186 while also reducing its susceptibility to proteolysis
187

.
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Extensive work has characterized the extent of IGFBP-1 phosphorylation and its
effects on its binding affinity towards IGF-I and IGF-I bioavailability. Phosphorylated
IGFBP-1 derived from HepG2 cell conditioned media results in a 6-fold increase in
affinity for IGF-I compared to non-phosphorylated IGFBP-1 188. Our lab further
established an association between phosphorylated IGFBP-1 and decreased IGF-I
bioactivity via IGF-1R autophosphorylation in vitro from several sources, including
amniotic fluid derived from FGR pregnancies and conditioned HepG2 cell media 189–191.
Although non-phosphorylated IGFBP-1 binds both IGF-I and IGF-II with similar
affinities, phosphorylation of IGFBP-1 increases its affinity towards IGF-I only 192.
We have demonstrated that IGFBP-1 is phosphorylated at six serine residues
(Ser95, 98, 101, 119, 169 and 174) (Figure 2) 179,193. Of these sites, Ser98, 101, 119 and
169 have been validated by alanine mutagenesis to mediate binding affinity and cause
varied responses to IGF-I 190. Previous stoichiometric analysis of IGFBP-1
phosphorylation sites in CHO cells demonstrated Ser101 as the major site of
phosphorylation (70%) and Ser119 (5%) and Ser169 (25%) as minor sites of
phosphorylation 181. IGFBP-1 mutations Ser98Ala and Ser169Ala maintained potent
inhibition of IGF-1R autophosphorylation in P6 cells although retained 42- and 34-fold
reduced binding affinity towards IGF-I, respectively. Ser101Ala and Ser119Ala
mutations, however, did not significantly inhibit IGF-1R autophosphorylation and
demonstrated 89- and 99-fold respective decreases in IGFBP-1 to IGF-I binding affinity
190

. Thus, Ser101 and Ser119 have been demonstrated as potent inhibitory

phosphorylation sites. However, the site and degree of IGFBP-1 phosphorylation rather
than total amount of total IGFBP-1 or phosphorylated IGFBP-1forms mediates the
functional effects of IGF-I bioactivity inhibition 194. We have previously demonstrated a
~300-fold increase in binding affinity for IGF-I due to hypoxic stimulation with primarily
Ser98 and Ser169 hyperphosphorylation compared to a ~30-fold increase in binding
affinity for IGF-I from leucine deprivation which primarily induces Ser119
hyperphosphorylation 194. The changes in IGF-I binding affinity were attributed to the
degree of specific site hyperphosphorylation which varied between hypoxia and leucine
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deprivation treatments where we demonstrated increased IGFBP-1 phosphopeptide peak
intensity against an internal IGFBP-1 control peptide 194.
The linker region contains Ser98, Ser101 and Ser119 while the C-terminal domain
contains Ser169 189, indicating that both phosphorylation within the linker region and Cterminal domain may mediate increased IGFBP-1 affinity for IGF-I by distinct structural
mechanisms. Our lab further characterized Ser101, Ser119 and Ser169 as upregulated
phosphorylation sites in amniotic fluid 189, umbilical cord plasma 177 and primary fetal
hepatocytes derived from a baboon model of FGR 177.

1.3.6

IGFBP-1 phosphorylation in FGR pregnancy
The phosphorylation status of IGFBP-1 in maternal and fetal compartments differ

throughout gestation. Martina et al., (1997) examined gestational-age dependent
phosphorylation of IGFBP-1 in several maternal and fetal compartments 195. In early
gestation, maternal serum contains primarily non-phosphorylated IGFBP-1 while nonpregnant maternal serum contains highly phosphorylated IGFBP-1. Maternal serum
derived IGFBP-1 in amniotic fluid at this time, is also primarily non-phosphorylated. By
mid-gestation, maternal serum contains all IGFBP-1 phosphoisoforms while amniotic
fluid contains all but the most highly phosphorylated isoforms. In late gestation, maternal
serum only contains the highly phosphorylated isoforms. Decidual IGFBP-1 production
and phosphorylation status seems to be temporally and inversely regulated by local IGFII levels which rises during normal pregnancy, resulting in predominance of nonphosphorylated IGFBP-1 196. The fetal liver however, consistently secretes highly
phosphorylated IGFBP-1 over the course of pregnancy 195.
Elevated fetal IGFBP-1 levels which directly affects circulating fetal IGF-I
bioactivity and therefore fetal growth 104 is additionally highly correlated with FGR. A
causal relationship between increased IGFBP-1 and decreased birthweight in a mouse
model overexpressing fetal liver IGFBP-1resulting in an 18% reduction in birthweight
197

. IGFBP-1 phosphorylation has not been extensively studied within the human fetal

liver, in part, due to limited human fetal liver availability. Several models of FGR have
instead been utilized for the better understanding of human fetal liver IGFBP-1
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phosphorylation. Rat and animal models have been used previously, however, differences
in IGFBP-1 primary structure between rat, mouse and human orthologs result in loss of
specific IGFBP-1 phosphorylation sites and is therefore insufficient in studying human
FGR 198. A well established maternal nutrient restricted (MNR) baboon model of FGR
199,200

based on 30% caloric restriction reduces fetal essential amino acid levels, fetal

weight and results in structural and functional changes in fetal organs 201,202 while being
associated with increased IGFBP-1 expression within the fetal liver 97. In respect to
differentiation factors, fetal hepatocytes and human hepatocellular carcinoma HepG2
cells share close proteomic and transcriptomic resemblances 72,203,204. HepG2 cells have
been used extensively, primarily by our laboratory, as a model for fetal hepatocytes in the
investigation of fetal IGFBP-1 phosphorylation 94,177–179,191,194.
The association of the degree of IGFBP-1 phosphorylation in maternal and fetal
compartments and amniotic fluid in human pregnancies have been previously
investigated though with contradictory results 177,182,186,189,190,196,205–210. However, our
team has demonstrated that the sites and degree of IGFBP-1 phosphorylation invariably
affect binding affinity towards IGF-I and IGF-I bioactivity 190,194. We further
demonstrated that the phosphorylation status of IGFBP-1 in amniotic fluid is altered
within FGR 211. IGFBP-1 hyperphosphorylation in amniotic fluid and umbilical cord
plasma 177 at sites which affect IGFBP-1 binding is elevated in FGR 189,210. Furthermore,
utilizing the well established MNR baboon model of FGR, our team has demonstrated
increased IGFBP-1 phosphorylation at Ser98, Ser101, Ser119, Ser169 and Ser174 in FGR
baboon fetal liver tissue during early and late gestation 94. Within HepG2 cells, our group
has demonstrated hypoxia and nutrient deprivation as determinant factors which induce
IGFBP-1 phosphorylation 178,179,194,212.

1.4

Kinases regulating IGFBP-1 phosphorylation

Phosphorylation of IGFBP-1 at sites known to mediate IGF-I binding 190 occur are
acidophilic Ser residues, containing either Asp or Glu residues following the
phosphoacceptor 191. These acidicophilic phosphorylation sites conform well to the
protein kinase CK2 consensus site (S/T-x-x-D/E) 213 which has been previously
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considered as and demonstrated in vitro to be the kinase phosphorylating IGFBP-1 214,215.
Another kinase, Fam20C or otherwise known as the genuine “Golgi casein kinase” 216,217
has been identified to phosphorylate a similar acidophilic consensus sequence to CK2 (Sx-E/pS) and has also been demonstrated to phosphorylate IGFBP-1 in vitro by CRISPR
knockdown 218. However, Fam20C does not mediate the phosphorylation of the most
important Ser98, Ser101 and Ser119 residues which mediate high affinity IGF-1 binding
and inhibition of IGF-1R autophosphorylation 190,218 whereas CK2 has been demonstrated
to mediate the phosphorylation of these distinct phosphorylation sites
Furthermore, IGFBP-1 contains consensus sequences for protein kinase A (PKA)
and protein kinase C (PKC) 165. PKA has been demonstrated to phosphorylate IGFBP-1
in vitro 186,214,215 and mediate IGFBP-1 transcription in decidual and endometrial cells 219,
however, we recently demonstrated that PKA does not mediate IGFBP-1 phosphorylation
in HepG2 cells 191. PKC, on the other hand, has been implicated to regulate IGFBP-1
expression in several cell types 220,221. Although PKC phosphorylates basic Ser/Thr
residues, we have previously demonstrated inhibition or knockdown of PKC reduced
IGFBP-1 phosphorylation at putative CK2 sites (Ser101, Ser119, Ser169) 191

1.4.1

Protein Kinase CK2 – Structure and phosphorylation
determinants
CK2 is ubiquitous in eukaryotic organisms and primarily exists as a tetrameric

enzyme consisting of two catalytic subunits (α or α’, in any combination) and two
regulatory subunits (β), adopting a structure in which CK2β dimers form the core of the
tetrameric enzyme 213.. CK2 phosphorylates Ser or Thr residues with a consensus
sequence of S/T-x-x-D/E, though Pro, Lys or Arg at the +1 position are unfavourable 222.
Furthermore, CK2 phosphorylation sites may follow hierarchal phosphorylation, which
allows for Ser phosphoacceptors outside of the canonical consensus sequence to be
phosphorylated if adjacent pSer residues occur at the +1 and +3 positions 223. However,
these phosphorylation determinants are not quintessential for CK2 phosphorylation of a
substrate 222,224.
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1.4.1.1

CK2 phosphorylation of IGFBP-1 and involvement in FGR

IGFBP-1 has been demonstrated to be phosphorylated by CK2 in HepG2 215 and
endometrial stromal cells 214. Our lab has demonstrated complete CK2 holoenzyme
silencing and independent CK2 subunit silencing decreasing IGFBP-1 phosphorylation
in HepG2 cells 177. Accordant with increases in IGFBP-1 phosphorylation in FGR and
models of FGR, CK2 activity is increased concomitantly 94,177,180,191.

1.4.2

Protein Kinase C – Initial Discovery
Cyclic nucleotide dependent kinases PKA and protein kinase G (PKG) were

discovered in the 1960s and 1970s, respectively and had paved the way to the discovery
of PKC 225,226. Analysis of mammalian PKG from rat brain tissue led to the discovery of
an active Mg2+ dependent enzyme termed protein kinase M (PKM), which could only be
detected upon repeated freeze and thaw cycles, leading to the idea that PKM may be a
proteolyzed active form of believed to be proteolytically cleaved from PKG by a Ca2+dependent protease based on their previous work 227,228. However, brain PKG activity was
curiously low thus the unknown parent protein of PKG was termed “proenzyme” (PKC).
Comparatively, PKM readily phosphorylated protamine and H1 histone and protamine
whereas the proenzyme recognized protamine but failed to phosphorylate H1 histone. A
two-step reaction assay measuring Ca2+ dependence and kinase activity for Ca2+dependent protease with proenzyme resulted in the first mechanistic discovery of PKC
where kinase activity was detected in both cytosolic and particulate fraction and that
particulate fraction “Ca2+-dependent protease” was not an enzyme as its mechanism
activated proenzyme instantaneously 229. Proenzyme was renamed to “protein kinase C”
as Ca2+ was regarded as its critical regulator. The initial discovery of active PKC within
the particulate fraction led to the discovery of the enzyme’s true nature of being
phospholipid dependent. Neutral lipids, glycolipids and phospholipids were extracted
from tissue and separated by column chromatography. PKC activity was determined to be
activated by neutral and glycolipid fractions and diacylglycerol (DAG) was determined
as the second messenger which activated PKC 230.
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1.4.2.1

Structure and Regulation of PKC

PKC comprises of a family of related Ser/Thr kinases involved in several signal
transduction pathways 231. The PKC family of kinases contain highly conserved, Cterminal catalytic domains, a regulatory N-terminal domain that maintains the enzyme in
an inactive conformation via an autoinhibitory pseudosubstrate and membrane targeting
modules known as C1 and C2. Based on the N-terminal domain structure, PKC isoforms
are categorized into subfamilies known as conventional (cPKC), novel (nPKC) and
atypical (aPKC) isoform based on their co-factor requirements. cPKC isoforms bind both
DAG and Ca2+, whereas nPKCs bind only DAG and aPKCs require neither DAG or Ca2+
for activity. The C1 domain mediates DAG/phorbol ester binding while the C2 domain
binds Ca2+. The C3 and C4 domains form the ATP and substrate-binding lobes of the
kinase core 232.

Figure 3. General schematic of conventional PKC isozymes. The length and relative
sizes of cPKC isoforms are variable. Variable regions (V1-V5) represent poorly
conserved sequences separating the highly conserved pseudosubstrate and C1-C4
domains. The novel PKC isoforms lack the C2 domain whereas the atypical PKC
isoforms lack the C2 domain and contain a C2-like domain preceding the
pseudosubstrate.
Numerous phosphorylations occur shortly after the biosynthesis of all PKC
izozymes to yield a stable, autoinhibited (by the pseudosubstrate) enzyme ready to be
activated by second messengers Ca2+ and DAG 233. Phosphoinositide-dependent kinase
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(PDK1) phosphorylates the conserved activation loop which triggers phosphorylation of
the turn motif and hydrophobic motif resulting in the adoption of the stable, autoinhibited
conformation 234. Activation of cPKC requires translocation from the cytosol to
membrane compartments 235. Membrane translocation is critically dependent upon
cytosolic Ca2+ concentrations which at basal conditions, is insufficient to active cPKC
and require a stimulus to induce cytosolic mobilization of Ca2+ which results in the
translocation of the enzyme to a membrane compartment for attachment 236. Attachment
to a membrane compartment following influx of cytosolic Ca2+ is further facilitated by
DAG, which allows the penetration of PKC into the membrane bilayer 237. Combination
of both high cytosolic Ca2+ concentration affording initial translocation and DAG
mediated membrane penetration facilitates activation of PKC 238.

1.4.2.2

PKC in FGR and Nutrient Sensitive Regulation of PKC

Evidence of PKC involvement in FGR is limited. Sugden and Langdown (2001)
examined placental insufficiency induced changes in the placental PKC isoform profile
and demonstrated increased expression of “pro-apoptotic” nPKC isoforms -δ and -ε and
reduced expression of “anti-apoptotic” cPKC isoforms -α, -βI and -βII 239. Upregulated
activity of PKCα, PKCε and expression of PKCβ, PKCβII and PKCδ within the cardiac
muscle of FGR offspring has also been demonstrated, though does not implicate
involvement of PKC in the development of FGR 240.
PKC expression and its activity are regulated by nutrient availability. Importantly,
nutrient sensitive regulation of PKC isoforms are differentially regulated based on tissue
and cell type. Leucine stimulates PKC autophosphorylation and subcellular redistribution
in skeletal muscle 241 and PKC activity in chicken hepatocytes 242. Low protein diets
however, inhibit PKC activity in pancreatic islets 243,244 while amino acid deprivation in
MCF-7 cells induce PKC expression 245. Furthermore, several PKC isozymes integrate
signals from the nutrient sensitive kinase mTOR, which may indicate a non-direct
nutrient sensitive function for PKC 246–248. PKC upregulation is additionally intimately
linked with attenuating nutrient transport in nutrient excess environments, possibly
representing a feedback mechanism for regulating bodyweight 249–252.
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1.4.2.3

Involvement of PKC in mediating IGFBP-1 phosphorylation

Conserved amino acid sequences in all six IGFBPs have previously elected PKC
as a possible kinase responsible for their direct phosphorylation 165. However, the basic
requirements of PKC consensus sequences exclude the possibility of direct PKC
phosphorylation at IGFBP-1 at sites which mediate IGF-I binding 190,232. PKC activation
has been previously demonstrated to induce IGFBP-1 expression in endometrial
carcinoma cells and HepG2 cells 220,221. Our previous work demonstrated a supporting
role for PKC in mediating IGFBP-1 phosphorylation at Ser101, Ser119 and Ser169 191.
While PKC contributes to IGFBP-1 phosphorylation, the specific isoform(s) involved,
and their respective role and mechanisms have not yet been elucidated.

1.5

Rationale, objective and hypothesis

1.5.1 Rationale: Amino acid availability dramatically affects cellular signaling in
several protein networks, resulting in altered protein expression. Cellular responses to
amino acid restriction include an increase in IGFBP-1 phosphorylation which is a key
constituent to FGR 71,178,193. IGF-I bioavailability is the vital determinant of fetal growth
and the phosphorylation of IGFBP-1 at several sites significantly increases its binding
affinity for IGF-I thus considerably reducing IGF-I bioactivity 104,111,190. The key
signaling mechanisms resultant of amino acid restriction and IGFBP-1 phosphorylation
have been explored in vitro and in vivo 94,178,180. Furthermore, previous studies have
demonstrated the involvement of multiple kinases regulating IGFBP-1 phosphorylation
under leucine deprivation 191. However, the role of an apparent supporting kinase, PKC,
has not been thoroughly investigated and the mechanisms involved in which it mediates
the phosphorylation of IGFBP-1 in leucine deprivation have not been elucidated.

1.5.2 Hypothesis: Leucine deprivation activates nutrient sensitive PKC resulting in
its translocation and induces its interaction with CK2, mediating fetal hepatic IGFBP-1
phosphorylation in vitro.
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1.5.3 Objective: The objective of this study was to determine the molecular
mechanisms surrounding the key kinases involved in IGFBP-1 phosphorylation and thus,
IGF-I bioavailability in leucine deprivation.
The specific aims to elucidate our objectives are as follows:
1. To investigate interactions between PKC, CK2 and IGFBP-1
2. Determine the PKC isoform involved in IGFBP-1 phosphorylation
3. To demonstrate nutrient sensitive regulation of PKC

1.6
1.6.1

Experimental models
HepG2 cells as a model for fetal hepatocytes

The fetal liver is the primary source of circulating fetal IGFBP-1 in vivo 166.
HepG2 cells are human liver carcinoma cells and are widely employed as a model for
human fetal hepatocytes due to their biotransformation properties and the similarities
amongst their transcriptome, proteome and secretome 203,204,253,254. IGFBP-1 mRNA is
induced in non-growth conducive environments in HepG2 cells, which applicably serves
our purposes in studying IGFBP-1 phosphorylation 174. We have extensively employed
HepG2 cells as a model for study of IGFBP-1 phosphorylation 94,177–179,191,194.
Additionally, we have validated the use of HepG2 cells as a model for fetal hepatocytes
utilizing cultured primary baboon hepatocytes 177.

1.6.2

Leucine deprivation model for nutrient restriction
Leucine is an essential amino acid with the most potent effects amongst amino

acids regarding protein synthesis and degradation, energy balance regulation and leptin
secretion 255. Leucine supplementation enhances protein synthesis in several tissue and
cell types 256. Leucine deficiency specifically and not essential amino acid or BCAA
deficiencies is implicated in the development of FGR. The distinct effects of leucine
separate from BCAA is capable of attenuating the effects of maternal protein
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undernutrition which induced growth restriction 84. Furthermore, deficiencies in
fetoplacental leucine transport results in significant reduction in feto-maternal leucine
ratios and fetal circulating leucine which are consistently identified in FGR 49,72,73,82,83.
Our laboratory has extensively used leucine deprivation (L0) as a model of nutrient
deprivation to induce IGFBP-1 phosphorylation in vitro with effects similar to maternal
nutrient restriction 94,177,178,191,194.

1.6.3

Baboon maternal nutrient restriction as a model of human
FGR
We utilized a well-established MNR baboon model of FGR instead of other

animal models such as rodents or sheep due to differences in placental organization and
IGFBP-1 phosphorylation 198,257,258. 30% caloric restriction used in this MNR baboon
model of FGR impairs placental development similarly to human maternal undernutrition
28,201

. Importantly, similar interspecies changes are also observed within the fetal hepatic

and placental IGF systems 97,111,201,259. Likewise with our utilization of leucine
deprivation in vitro, we have previously employed this MNR baboon model of FGR to
study IGFBP-1 phosphorylation in relation to CK2, mTOR and the AAR 94,177.

2
2.1

« Material and Methods

HepG2 cell culture and leucine deprivation

treatments
I utilized human hepatocellular carcinoma HepG2 cells as a model for fetal
hepatocytes due to their close proteomic and transcriptomic resemblance to fetal
hepatocytes in respect to differentiation factors 203,204,253. The similarities of HepG2 cells
to fetal hepatocytes further extends to cultured primary baboon fetal liver cells 177,260.
HepG2 cells at 85% confluency were plated at 5x105 and then allowed to adhere for 16
hours. Cells were starved for 16 hours and subsequently cultured in custom DMEM/F12
media containing either 450 µM (L450) or 0 µM (L0) of leucine for 24 hours as
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previously described 178,194. Conditioned cell media (CM) was collected and cells from
L450/L0 were lysed using lysis buffer (Cell Signaling Technologies, Beverly, MA).

2.2

Immunoprecipitation

Immunoprecipitation (IP) of IGFBP-1, CK2β and PKC was performed using
HepG2 cell lysate. For each IP, 100 μL of 50% Protein A Sepharose slurry (GE Health
Care, Canada) was coupled with IGFBP-1 mAb 6303 (Medix Biochemica, Kauniainen,
Finland), polyclonal CK2β (YenZyme, USA) or polyclonal Pan-PKC (SAB4502356,
Sigma-Aldrich, USA) respectively. Antibodies were diluted in 5x HEPES buffer (50 mM
HEPES, 750 mM NaCl, 15 mM EDTA) and coupled to Protein A Sepharose beads.
HepG2 cell lysate (200 μg total protein) were buffer exchanged against PBS with
0.1% Tween (PBS-T) using 10K MWCO Ultracel centrifugal filter units (Millipore,
Ireland) as described previously 212. Unbound proteins were removed (flow-through). For
Western blot analysis, proteins from a small aliquot were eluted from Sepharose beads
with 50 μL elution buffer (8 M urea, 5% SDS, 50 mM Tris-HCl pH 7.8) and stored –
20°C. The remaining beads were processed as described below for mass spectrometry.

2.3

SDS-PAGE and Western blotting

Protein separations were conducted using SDS-PAGE with Precision Plus
Protein™ All Blue protein standards (BioRad Laboratories, Canada). Proteins were
transferred to nitrocellulose membranes, and blocking was performed using either 5%
skim milk or 5% bovine serum albumin (BSA) in Tris-buffered saline (TBS) with 0.1%
Tween-20 (TBST).
For IGFBP-1 secretion, equal volumes (30-50 μL) of direct HepG2 CM were
obtained using equal number of plated cells used for normalization due to the absence of
a secretory internal control. Previously validated 177,261 custom phospho-site specific
IGFBP-1 antibodies for pSer101 (1:500), pSer119 (1:2000) and pSer169 (1:250)
(YenZyme, USA) and a custom polyclonal total IGFBP-1 (1:10,000) (a gift from Dr.
Robert Baxter, Australia) were used as primary antibodies. For PKCα, pIGF-1RβTyr1135
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and IGF-1Rβ, equal amounts of total protein in cell lysate from HepG2 cells (30-50 µg)
or from fetal liver extracts were used. Monoclonal PKCα antibody (1:1000) (NB600-201;
Novus Biologicals, USA), monolonal pIGF-1RβTyr1135 (1:1000) (DA7A8; Cell Signalling
Technologies, USA), polyclonal IGF-1Rβ (1:250) (sc-713; Santa-Cruz Biotechnology,
USA) and loading control β-actin (sc-47778; Santa Cruz Biotechnology, USA) were
used. Calnexin (1:1000) (610523; BD Biosciences; USA) and α-tubulin (1:20,000)
(T5168; Sigma-Aldrich, USA) were used as controls for membrane and cytosol enriched
fractions, respectively. Secondary antibodies were HRP-conjugated goat anti-rabbit IgG
(1:10,000) and goat anti-mouse IgG (1:10,000) (BioRad, Canada). Precision ProteinTM
StepTactin-HRP conjugate (BioRad, Canada) was used to visualize the protein ladder and
β-actin was used to account for any differences in protein load and transfer. Enhanced
chemiluminescence (ECL) reagents were employed for detection of proteins 262. Images
were captured using the Quantity One Molecular Imager VersaDoc imaging system
(BioRad, Canada) and band intensities were subjected to densitometrical analyses using
Image Lab (BioRad, Canada).

2.4

Parallel Reaction Monitoring Mass Spectrometry

(PRM-MS)
In-solution digestion of the IP samples was performed as described 179. Peptide
digests were desalted using C18-Zip Tip and dried in a Thermo SpeedVac. After
desalting and drying, samples were loaded onto a Thermo Easy-Spray analytical column
(75 µm i.d. × 500 mm) C18 column with an Easy-nLC 1000 chromatography pump. For
each analysis, we reconstituted peptides in 20 µL of 0.1% trifluoroacetic acid (TFA) and
loaded 4 µL onto the column. Peptides were separated on a 125 min (5–40% acetonitrile)
gradient. Mass spectra were collected on a Q-Exactive hybrid quadrupole-Orbitrap mass
spectrometer coupled to an Easy-nLC 1000 system (ThermoFisher, USA). The
spectrometer was set in full MS/data-dependent-MS2 TopN mode: mass analyzer over
m/z range of 400-1600 with a mass resolution of 70,000 (at m/z = 200), 35 NCE
(normalized collision energy), 2.0 m/z isolation window and 15 second dynamic
exclusion. The isolation list (not shown) with the Mass [m/z] and the sequences of the
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peptides used to identify PKC and IGFBP-1 by PRM-MS were recorded. Each trace on
the chromatograph represents the detection of each individual transition ion used to
monitor PKC detection. Retention time indicates that transition ions result from the same
parent peptide (correlating with the time that the parental peptide had eluted from the C18
column). Data were generated by PRM-MS using isolation lists that were specific to PKC
and IGFBP-1.
IGFBP-1 internal peptide (NH2-ALPGEQQPLHALTR-COOH) was used to
normalize phosphorylated IGFBP-1. With two possible IGFBP-1 phosphorylation sites
(dual), specific transitions were used to distinguish single-site-phosphorylation from each
other (specifically, y14, b6 and b9 ions for pSer169 and pSer174; y12 and b15 ions for
pSer98 and pS101).

2.5

PKCα siRNA silencing

HepG2 cells were plated at 75% confluence in 6 well plates. Silencing using
siRNA against PKCα (SASI_Hs01_00018816; Sigma-Aldrich, USA) in HepG2 cells was
achieved using transfection 177 with 80 nM siRNA and 5 μL Dharmafect transfection
reagent (Thermo Scientific, USA) in regular, serum free DMEM:F12 for 24 hours.
Transfection media was replaced with L450 or L0 media 24 hours post transfection. CM
and cell lysates were collected from HepG2 cells 48 hours post L450 or L0 treatment as
described above. Western immunoblot analysis was used to determine the efficiency of
target silencing, total IGFBP-1 secretion and IGFBP-1 phosphorylation at three sites
(Ser101, 119 and 169).

2.6

Immunofluorescence (IF)

HepG2 cells were seeded at 2.2x105 on 0.1% poly-L-lysine coated coverslips in 6
well plates, followed by L0 treatment. Cells were fixed with 4% paraformaldehyde for 1
hour at 4°C, permeated in 0.25% Triton X-100 for 10 minutes and blocked with Dako
Background Sniper (Biocare Medical, USA) for 10 minutes.
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Several combinations of primary antibodies were used in dual IF: i) mouse mAb
PKCα (1:250) and rabbit polyclonal IGFBP-1 (1:2500), ii) mouse mAb PKCα and rabbit
polyclonal CK2β (1:500) and mouse IGFBP-1 mAb 6303 (1:500) and rabbit polyclonal
CK2β (1:500) which were incubated overnight at 4°C. Single IF staining was performed
using mouse mAb PKCα (1:250). Secondary antibodies anti-mouse Alexa Fluor 488
(1:400) and anti-rabbit Alexa Fluor 568 (1:400) were applied to cells and incubated for
45 min. Phalloidin 568 (1:20) was used to stain the cytosol in single IF staining
experiments with PKCα (ThermoFisher, Canada). Cells were then counterstained with
DAPI (1:300) (Life Technologies, Canada). Negative controls used were rabbit (X0903)
and mouse pre-immune serum (X0931) at 4 μg/mL (Agilent Technologies, Santa Clara,
CA). Coverslips were mounted (Fisher Scientific, Fairlawn, NJ) with Prolong Gold
Mounting Media (ThermoFisher, Canada) and dried overnight prior to imaging on an
Nikon Inverted T12E Deconvolution Microscope (Nikon Instruments Inc. USA)

2.7

Proximity ligation assay (PLA)

HepG2 cells were seeded at 2.2x105 on 0.1% poly-L-lysine coated coverslips in 6
well plates, followed by L0 treatment as described earlier. Cells were fixed and
permeabilized as in IF. Primary antibody combinations and incubation time remained the
same as in dual IF.
Fixed HepG2 cells blocked with Duolink blocking solution (Sigma Aldrich, USA)
were used for PLA using PLA secondary probes (anti-rabbit plus and anti-mouse minus)
diluted 1:5 in Duolink antibody diluent (Sigma-Aldrich, USA) and incubated for 1 hour
at room temperature. Subsequent ligation and amplification were performed according to
manufacturer’s instructions (Sigma-Aldrich, USA). Samples were mounted with provided
mounting media containing DAPI counterstain and image acquisition was acquired on an
AxioImager Z1 Epifluorescent Microscope (Carl Zeiss Canada Ltd.). Quantification was
performed through automated counting of PLA signals and cell nuclei using ImagePro
Premier and normalized by the cell number. Data were analyzed in GraphPad Prism 6.
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2.8

Treatment of HepG2 cells by pharmacological

kinase inhibitors and activators
HepG2 cells were plated at 75% confluence and starved for 16 hours in 0% FBS
(DMEM:F12) prior to treatments with inhibitors and/or activators. Following dose
dependency treatments, subsequent experiments utilized PKC activator phorbol 12myristate 13-acetate (PMA) at 100 nM; PKC inhibitor bisindolylmaleimide II (Bis II) at
7.5 μM 191 and CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) at 10 μM.
Following 24 hrs of pharmacological treatment, CM and cell lysate were collected using
lysis buffer (Cell Signaling Technologies, Beverly, MA) with protease and phosphatase
inhibitor cocktails (P8340, P5726, P0044; Sigma-Aldrich, St. Louis, MO). Protein
contents determined by Bradford assay (BioRad Laboratories, Canada) and samples were
stored at –20°C.

2.9

Subcellular fractionation of HepG2 cells by

differential centrifugation
HepG2 cells at 80% confluency were detached with 10 mM EDTA in PBS for 35
min. Cells were collected and centrifuged at 400 g for 4 min and resuspended 1:5 in
homogenization buffer (0.25 M sucrose, 5 mM HEPES, pH 7.4, cold) with protease and
phosphatase inhibitors (same as used for cell lysis). Cells were homogenized utilizing a
Polytron PT3000 (Kinematica AG, Lucerne, Switzerland). Post-nuclear cell lysate was
obtained by nuclear extraction by centrifugation at 2,000 g for 10 min. Post-nuclear cell
lysate was centrifuged at 105,000 x g for 1 hr and the supernatant (cytosolic fraction) was
collected, the pellet (membrane fraction) rinsed with homogenization buffer and then
resuspended in homogenization buffer containing 0.1% Triton X-100. The supernatant
and pellet fractions were then sonicated and stored at –20°C for analysis by Western blot.

2.10

Confocal image acquisition

Images were captured with a 63× Plan-Apochromat oil immersion lens on a Leica
SP8 confocal microscope. The acousto-optical beamsplitters were tuned to avoid all
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crosstalk between channels. Alexa 488 was excited with a blue 20 mW 488 nm HeNe
laser. For Alexa 568, a green 20 mW 552 nm HeNe laser was used for excitation. DAPI
signal was excited with a 50 mW 405-50 Diode.

2.11

IGF-1R autophosphorylation assay

I employed an IGF-1R autophosphorylation assay as previously described 261. In
brief, mouse embryo fibroblast P6 cells (a BALB/c3T3 cells derivative) which overexpress human IGF-1R (a kind gift from Dr. R Baserga, Thomas Jefferson University,
Philadelphia, PA) were seeded at 4x105 in 6-well plates and allowed to adhere overnight.
P6 cells were starved for 6 hours, then treated with HepG2 cell conditioned media from
several treatments containing equal amounts of total IGFBP-1 incubated for 2 hours with
recombinant human IGF-I (25 ng/mL) for 15 minutes at room temperature. P6 cells were
lysed and equal amount of total protein (40 μg) was loaded for Western blotting to assess
changes in IGF-1R autophosphorylation using pIGF-1RβTyr1135 antibody.

2.12

Cell viability assay

Standard Trypan Blue exclusion assay was utilized to ensure that pharmacological
or siRNA treatments did not negatively impact cell viability. Following treatments, cells
were lifted and re-suspended in 10% FBS media and diluted 1:1 with 0.4% trypan blue
and counted manually with a haemocytometer.

2.13

Preparation of baboon fetal liver extracts

Baboons (Papio cynocephalus hamadryas, P. cynocephalus anubis, and P.
hamadryas anubis) from the Southwest National Primate Research Center were housed in
outdoor cages permitting social and physical activity and controlled dietary intake 263. In
this MNR model, mothers were fed 70% of the ad libitum control mothers (Purina
Monkey Diet 5038). Pregnancy was confirmed at GD 30 by ultrasound and Cesarean
section was performed at GD 120 and GD 165 (full term GD 185) described previously
263

. Fetuses were sourced solely from singleton pregnancies. Fetal liver tissue was frozen

at −80°C. Frozen pieces ( –80C) of the left lobe (~0.2 g) of fetal liver (GD 120; n=19;
male=11; female=8, GD 165; n=24, male=10; female=14) were homogenized using lysis
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buffer with protease and phosphatase inhibitor cocktails described in detail previously 94.
The homogenate was centrifuged, and the clear supernatant was stored at –80°C.

2.14 Immunohistochemistry (IHC) using baboon fetal
liver tissue
Tissues sections (5 μm) from GD matched control and MNR liver tissue of the
left lobe were mounted on the same microscope slides and baked overnight at 45°C.
Slides were deparaffinized in Xylene, rehydrated through graded ethanol series, then
washed in tap water followed by PBS. Endogenous peroxidases were blocked in 3%
hydrogen peroxide, and tissues were incubated with Background Sniper blocking solution
(Biocare Medical, LLC., Pacheco, CA). Slides were incubated overnight at 4°C with
mouse PKCα mAb (1:250) (Novus Biologicals, USA) in antibody diluent (Dako, Agilent
Technologies, Santa Clara, CA). Secondary antibodies (anti-mouse horseradish
peroxidase polymer complex, ImmPRESS® HRP Reagent Kit, Vector Laboratories,
Burlingame, CA) were incubated for 45 minutes at room temperature. Sections were
treated with 3,3’-diaminobenzidine (DAB) substrate (ImmPACT® DAB Peroxidase
Substrate Kit, Vector Laboratories, Burlingame, CA) for two minutes, counter-stained
with Modified Mayer’s Haematoxylin (ThermoFisher, USA) for 20 seconds, rinsed,
immersed in tap water for 4 minutes, then dehydrated through graded alcohols, cleared
with Xylene, and mounted with Permount (Fisher Scientific, Inc.) for 30 seconds. Images
were captured with a Zeiss AxioImager Z1 Microscope (Carl Zeiss Canada Ltd., North
York, ON Canada) using brightfield imaging with a 40x oil immersion lens.

2.15

Data presentation and statistics

Data was analyzed using GraphPad Prism 6 (GraphPad Software, USA).
Quantification of controls were assigned an arbitrary value of 1 and treatments were
expressed relative to this mean. All quantified experiments were performed at minimum
in triplicate. Statistical significance was tested using paired t-test, one-way analysis of
variance (ANOVA) or two-way ANOVA with Dunnett’s Multiple Comparison Post-Test
and expressed as the mean + SEM. Significance was accepted at p<0.05.
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3

Results

3.1 IGFBP-1, CK2β, and PKCα reciprocally coimmunoprecipitate
To identify the involvement of PKC in IGFBP-1 phosphorylation under L0, I first
performed simultaneous co-immunoprecipitations (co-IPs) of IGFBP-1, CK2β, and PanPKC (recognizes the conserved activation-loop of PKC isoforms) in HepG2 cells
cultured with (L45) or without (L0) leucine. I performed western blot analysis to detect
IGFBP-1, PKCα and CK2β in L450 and L0 co-IPs (Figure 4). Here, I demonstrate that
PKCα co-IPs IGFBP-1 in L0 and that PKCα fails to co-IP IGFBP-1 in L450 (Figure 4A).
Similarly, PKCα also reciprocally co-IPs CK2β which occurs only in L0 conditions
(Figure 4B). However, IGFBP-1 and CK2β reciprocally co-IP both in L450 and L0
(Figure 4C). These data demonstrate that although IGFBP-1 is associated with CK2β in
both L450 and L0, PKCα only co-IPs with IGFBP-1 and/or CK2β specifically in L0.
These findings provide convincing evidence that PKCα is a nutritionally sensitive kinase
responding to L0 conditions resulting in enhanced protein-protein interactions with both
IGFBP-1 and CK2β. Furthermore, IP with rabbit pre-immune IgG used as a negative
control failed to immunoprecipitate IGFBP-1, CK2β or PKCα supporting the rigor of our
approach.
In order to identify and confirm the PKC isoform which co-IPs with IGFBP-1 or
with CK2β in L0, PKC peptides were analyzed by PRM-MS. PRM-MS detected fifteen
PKC specific peptides from the respective IGFBP-1 and CK2β IPs collected from L0
cultured HepG2 cell lysates (Figure 5). Three out of 15 detected PKC specific peptides
were homologous peptides unique to conventional PKC isoforms while 12 of 15 were
unique solely to PKCα (Table 1). Each detected PKC peptide spawned at least four
daughter ions with co-detection of the parent immunoprecipitating protein indicating
robust detection (Figure 5B-D). IGFBP-1 peptides were co-detected from both IGFBP-1
and CK2β IPs with specific detection of peptides containing IGFBP-1 phosphorylation
sites Ser98, Ser101, Ser119 and Ser169 with the Ser119 peptide being detected with the
highest intensity (Figure 5E). This targeted MS approach corroborates Western blot
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findings (Figure 4); IGFBP-1 co-IPs CK2β and PKCα; CK2β co-IPs IGFBP-1; and
PKCα, and Pan-PKC co-IPs IGFBP-1 and CK2β in L0. PRM-MS data provide strong
evidence that the PKC isoform involved in L0 is PKCα which is the specific interacting
PKCα isoform with CK2 and IGFBP-1 in L0.

Figure 4. IGFBP-1, CK2β and PKCα reciprocally co-immunoprecipitated in L0
conditions. HepG2 cells were cultured in L450 and L0 media, lysed and
immunoprecipitated (IP) using total IGFBP-1 (mAb 6303), polyclonal CK2β, polyclonal
pan-PKC antibodies and rabbit pre-immune serum (IgG). (A) IP of IGFBP-1 and PKCα
demonstrating reciprocal IGFBP-1+PKCα co-IP in L0. (B) IP of PKCα and CK2β
demonstrating reciprocal PKCα+CK2β co-IP in L0. (C) IP of IGFBP-1 and CK2β
demonstrating reciprocal IGFBP-1+CK2β co-IP in L450 and L0. The IP’d proteins were
immunoblotted for total IGFBP-1 using polyclonal IGFBP-1, polyclonal CK2β, and mAb
PKCα antibodies. IP using rabbit IgG failed to IP IGFBP-1, PKCα and CK2β.
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Figure 5. PKC interaction with IGFBP-1 and CK2β in L0. HepG2 cells cultured in L0
media were independently IP’d using anti-IGFBP-1 and anti-CK2β antibodies and
analyzed by PRM-MS. (A) Detection of PKC peptides by PRM-MS from IGFBP-1
immunoprecipitation. Chromatogram shows total transitions for 15 PKC-specific
peptides, each peaks monitor at least 4 daughter ions. (B-D) Representative spectra of
each daughter ion used to detect the presence of PKC from IP samples. (E) Co-detection
of IGFBP-1 protein. Chromatogram shows total transitions for 4 IGFBP-1 peptides, each
peak monitors at least four daughter ions. All samples were doubly digested by trypsin
and Asp-N protease and C18 cleaned prior to MS.
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Table 1. Detection of PKCα peptides with shared homology among conventional
PKC isoforms. IGFBP-1 and CK2β immunoprecipitation from L0 cultured HepG2 cells
co-immunoprecipitated homologous cPKC and PKCα specific peptides detected by
PRM-MS.
Peptide
number

ID

Sequence

cPKC Homology

1

█

T.DFIWGFGKQGFQCQVCCFVVHK.R [54, 75]

PKCα + PKCβ +
PKCβII

2

█

K.RCHEFVTFSCPGA.D [76, 88]

PKCα + PKCβ +
PKCβII

3

█

K.IHTYGSPTFCDHCGSLLYGLIHQGMK.C [105,
130]

PKCα

4

█

C.DHCGSLLYGLIHQMKC.D [115, 131]

PKCα

5

█

C.DMNVHKQCVINVPSLCGM.D [135, 152]

PKCα

6

█

K.QCVINVPSLCGMDHTEK.R [141, 157]

PKCα

7

█

K.TIRSTLNPQWNESFTFK.L [213, 229]

PKCα

8

█

R.STLNPQWNESFTFKLK.P [216, 231]

PKCα

9

█

N.DFMGSLSFGVSELMKMPASGWYK.L [253,
275]

PKCα

10

█

K.MPASGWYKLLNQEEGEYYNVPIPEG.D [268,
292]

PKCα

11

█

K.LLNQEEGEYYNVPIPEG.D [276, 292]

PKCα

12

█

K.PPFLTQLHSCFQTVDR.L [396, 411]

PKCα

13

█

R.LYFVMEYVNGGDLMYHIQQVGK.F [412, 433]

PKCα

14

█

K.FKEPQAVFYAAEISIGLFFLHK.R [434, 455]

PKCα

15

█

P.DYIAPEIIAYQPYGK.S [502, 516]

PKCα + PKCβ +
PKCβII + PKCγ

3.2 PKCα siRNA silencing reduces IGFBP-1
phosphorylation
To confirm the mechanistic involvement of PKCα in mediating IGFBP-1
phosphorylation in L0, I silenced the PKCα isoform in HepG2 cells cultured with and
without leucine. PKCα siRNA reduced PKCα expression in both L450 and L0 conditions
with high efficiency (–71% (p = 0.0003) and –70% (p = <0.0001) respectively) (Figure
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A3). PKCα knockdown reduced total IGFBP-1 secretion by –51% (p = 0.015) in L450
and –36% (p = 0.0428) in L0 compared to their respective scramble siRNA controls.
Further PKCα knockdown prevented L0-mediated induction of total IGFBP-1 secretion
which was reduced to levels comparable to scramble siRNA transfected L450 treatment
(–1%, p = 0.96) (Figure 6A).
PKCα knockdown affected all three IGFBP-1 phosphorylation sites (Figure 6BD) both with and without leucine. In L450, PKCα knockdown reduced pSer101 by –78%
(p = 0.0035), pSer119 by –67% (p = 0.0106) and pSer169 by –75% (p=0.0193). In L0,
PKCα knockdown also reduced pSer101 by –56% (p = 0.0014), pSer119 by –39% (p =
0.005) and pSer169 by –39% (p = 0.0086).
Furthermore, PKCα knockdown reduced L0 mediated induction of IGFBP-1 at
pSer101 (–37%, p = 0.0309) and IGFBP-1 pSer119 (–21%, p = 0.0447) compared to
L450 transfected with scrambled siRNA (Figure 6B, C). Overall, these data suggest that
the PKCα is involved in mediating both the increased total IGFBP-1 secretion and the
IGFBP-1 hyperphosphorylation in response to L0.
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Figure 6. The effect of PKCα silencing on IGFBP-1 secretion and phosphorylation.
HepG2 cells were treated with scrambled or PKCα siRNA for 24 hours and subsequently
cultured in L450 or L0 media for 48 hours (n=3 each). Representative western blots of
conditioned HepG2 CM indicating (A) total IGFBP-1 and IGFBP-1 phosphorylation at
(B) Ser101, (C) Ser119 and (D) Ser169. Values are displayed as mean + SEM. *p< 0.05,
**p= 0.001-0.05, ***p < 0.0001 versus control; One-way analysis of variance; Dunnet’s
Multiple Comparison Test; n=3.
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3.3 Immunofluorescence staining and proximity ligation
assay indicate PKCα + IGFBP-1 and PKCα + CK2β
interactions are induced by leucine deprivation
I performed dual immunofluorescence (IF) to investigate cellular staining as an
additional alternative approach to investigate potential interactions between
PKCα+IGFBP-1 (Figure 7). Dual IF of PKCα+IGFBP-1 (Figure 7A) demonstrates
mostly cytosolic PKCα (Figure 7A; i, v) and IGFBP-1 (Figure 7A; ii, vi) staining with
more pronounced perinuclear IGFBP-1 staining in L0. Merged channel images (Figure
7A; iii, vii) of PKCα+IGFBP-1 demonstrate greater yellow fluorescence, indicating an
increased overlap between PKCα and IGFBP-1 fluorescence signals suggesting increased
co-localization between PKCα and IGFBP-1 as compared to L450 conditions.
I then employed the highly sensitive and specific in situ proximity ligation assay
(PLA) complementary to dual IF for PKCα+IGFBP-1 (Figure 7B). Within HepG2 cells
cultured in L450, limited PLA signals were observed (Figure 7B; a). PLA signals
between PKCα+IGFBP-1 were induced by L0 (Figure 7B; b). L0 significantly increased
PKCα+IGFBP-1 proximity reactions by +193% (p < 0.0001) (Figure 7B; d).
I then investigated a potential PKCα+CK2β interaction in L0 utilizing similar
dual IF staining which demonstrated strong co-localization of PKCα+CK2β in L450 and
L0 (Figure 8A). Furthermore, PLA demonstrated an abundance of proximity signals
between PKCα+CK2β in L450 (Figure 8B; a) and L0 (Figure 8B; b). Automated
quantification of PLA signals demonstrated a modest increase in PLA signals derived
from PKCα and CK2β proximity signals in L0 compared to L450 (+24%, p = 0.0293)
(Figure 8B; d). Considering the failure to detect co-IP of PKCα and CK2β in L450
(Figure 4B), the abundance of proximity reactions between PKCα+CK2β in L450
(Figure 8B; a) may be due to the ubiquitous nature of both proteins 213,264. However,
successful co-IP of PKCα and CK2β and the increase of PKCα+CK2β PLA signals in L0
indicate that a limitation in leucine availability induces a PKCα+CK2β interaction.
Overall, PLA indicates close proximity and potentially increased interactions of both
PKCα+IGFBP-1 and PKCα+CK2β in HepG2 cells cultured under L0.
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Furthermore, we previously found that IGFBP-1+CK2β interactions were induced
in hypoxia in HepG2 cells 212. Here, I examined IGFBP-1+CK2β interactions in L0
(Figure 9) in HepG2 cells. Co-localization between IGFBP-1 and CK2β were similarly
induced by L0 (Figure 9A). Complementary PLA demonstrated an +60% increase (p =
0.0131) in IGFBP-1+CK2β proximity reactions (Figure 9B; d).
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Figure 7. L0 mediates PKCα interaction with IGFBP-1. HepG2 cells were cultured in
L450 or L0 media and (A) immunostained to visualize (i, v) PKCα (green) with (ii, vi)
IGFBP-1 (red). (iii, vii) Merged images demonstrate co-localization of PKCα and
IGFBP-1. (iv, viii) Region of interest within merged channel images. (B) Proximity
ligation assay (PLA) for PKCα and IGFBP-1 in (a) L450 and (b) L0 conditions. (c)
Region of interest of proximity interactions between PKCα and IGFBP-1 in L0
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conditions. (d) Number of PLA signals (red dots) per cell for PKCα and IGFBP-1
proximity reactions in HepG2 cells cultured in L450 and L0 media. Values are displayed
as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.0001 versus control; paired t-test;
Dunnet’s Multiple Comparison Test; n=3. Scale bars: 20 μm.
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Figure 8. L0 mediates PKCα interaction with CK2β. HepG2 cells were cultured in
L450 or L0 media and (A) immunostained to visualize (i, v) PKCα (green) with (ii, vi)
CK2β (red). (iii, vii) Merged images demonstrate co-localization of PKCα and CK2β. (iv,
viii) Region of interest within merged channel images. (B) Proximity ligation assay
(PLA) for PKCα and CK2β in (a) L450 and (b) L0 conditions. (c) Region of interest of
proximity interactions between PKCα and CK2β in L0 conditions. (d) Number of PLA
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signals (red dots) per cell for PKCα and CK2β proximity reactions in HepG2 cells
cultured in L450 and L0 media. Values are displayed as mean + SEM. *p< 0.05, **p=
0.001-0.05, ***p < 0.0001 versus control; paired t-test; Dunnet’s Multiple Comparison
Test; n=3. Scale bars: 20 μm.
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Figure 9. L0 mediates IGFBP-1 interaction with CK2β. HepG2 cells were cultured in
L450 or L0 media and (A) immunostained to visualize (i, v) IGFBP-1 (red) with (ii, vi)
CK2β (green). (iii, vii) Merged images demonstrate co-localization of PKCα and CK2β.
(iv, viii) Region of interest within merged channel images. (B) Proximity ligation assay
(PLA) for PKCα and CK2β in (a) L450 and (b) L0 conditions. (c) Region of interest of
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proximity interactions between PKCα and CK2β in L0 conditions. (d) Number of PLA
signals (red dots) per cell for PKCα and CK2β proximity reactions in HepG2 cells
cultured in L450 and L0 media. Values are displayed as mean + SEM. *p< 0.05, **p=
0.001-0.05, ***p < 0.0001 versus control; paired t-test; Dunnet’s Multiple Comparison
Test; n=3. Scale bars: 20 μm.

45

3.4 Pharmacological inhibition and activation of PKC
demonstrates that PKC mediates IGFBP-1 phosphorylation
Next, I investigated whether PKC inhibition with Bis II and activation with PMA
in HepG2 cells cultured with and without leucine alter phosphorylation of IGFBP-1
(Figure 10). While total IGFBP-1 secretion in cell media (CM) was increased in response
to L0 (+162%, p=0.014), PKC inhibition by Bis II reduced L0 mediated increases in
IGFBP-1 secretion (–57%, p=0.02). Bis II also reduced total IGFBP-1 secretion in L450
(–86%, p=0.0004). On the other hand, induction of PKC by PMA enhanced total IGFBP1 secretion both in L0 (+912%, p=0.0013) and in L450 (+649%, p=0.016) (Figure 10A).
The effects of Bis II and PMA were also tested on phosphorylation of IGFBP-1.
Phosphorylation at all three IGFBP-1 sites were significantly induced in response to L0
(pSer101 +376%, p=0.009; pSer119 +110%, p=0.033; pSer169 +404%, p=0.008). Bis II
treatment largely prevented IGFBP-1 phosphorylation induced by L0 (pSer101 –78%,
p=0.009; pSer119 –66%, p=0.017; pSer169 –89%, p=0.0073) (Figure 10B-D), resulting
in no significant difference between IGFBP-1 phosphorylation in L450 and L0 with Bis
II. PKC inhibition by Bis II in L450 reduced IGFBP-1 phosphorylation (pSer101 –80%,
p=0.008; pSer119 –77%, p=0.01; pSer169 –78%, p=0.002).
PMA induced IGFBP-1 phosphorylation in L0 at pSer101 and pSer169 (pS101
+443%, p=0.03; and pSer169 +311%) but to a lesser extent than observed in L450
(pSer101 +1013%, p=0.02; pSer119 +121%, p=0.016; pSer169 +1644%, p=0.0131)
(Figure 10B, D). However, PKC induction by PMA in L0 did not induce IGFBP-1
phosphorylation at pSer119 (+11%, p=0.58) (Figure 10C). Overall, these data led us to
conclude that PKC inhibition leads to reduced IGFBP-1 and secretion and
phosphorylation while PKC activation increases both IGFBP-1 secretion and
phosphorylation, providing strong evidence for a key role of PKCα in IGFBP-1
phosphorylation and secretion in HepG2 cells Furthermore, PKC inhibition prevented
L0-induced IGFBP-1 phosphorylation and secretion and L0 prevented PMA induced
IGFBP-1 phosphorylation specifically at pS119 (+11%, p=0.58) indicating that PKC
mediates L0 induced IGFBP-1 phosphorylation particularly at Ser119 which is consistent
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with our previous findings 194. Heat map analysis derived from PRM-MS data was then
utilized to gain a visual overview and demonstrate that PKC contributes to IGFBP-1
phosphorylation at specific dual sites. HepG2 cells treated with Bis II, PMA and 4,5,6,7tetrabromobenzotriazole (TBB), an ATP site selective inhibitor of CK2 singly and in
combination clearly demonstrated the respective expected changes in phosphorylation
sites in response to kinase inhibition and activation (Figure 11). Dual phosphorylation
site analysis of IGFBP-1 at Ser169+Ser174 (Figure 11A) and at Ser98+Ser101 (Figure
11B) within targeted doubly phosphorylated peptides identified in relation to their
relative retention time of an IGFBP-1 internal peptide demonstrated similar findings to
our Western blot data (Figure 10). In brief, PKC inhibition and activation with Bis II and
PMA universally reduced and induced IGFBP-1 phosphorylation atSer169+174 and
Ser98+101, respectively Treatment with Bis II+PMA expectedly minimized the induction
of IGFBP-1 phosphorylation by PMA treatment. CK2 inhibition with TBB additionally
reduced IGFBP-1 phosphorylation. TBB in conjunction with PMA further mediated the
effects of PMA alone on induction of IGFBP-1 phosphorylation, suggesting that PKC
and CK2 act in concert in mediating IGFBP-1 phosphorylation.
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Figure 10. PKC mediates IGFBP-1 phosphorylation. HepG2 cells were treated with
Bis II (7.5 μM) and PMA (100 nM) and cultured with (L450) and without (L0) leucine.
Representative western blots of HepG2 CM indicating (A) total IGFBP-1 and IGFBP-1
phosphorylation at (B) Ser101, (C) Ser119 and (D) Ser169. Values are displayed as mean
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+ SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.0001 versus control; One-way analysis of
variance; Dunnet’s Multiple Comparison Test; n=3.
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Figure 11. Relative IGFBP-1 phosphorylation detected by PRM-MS. Chromatogram
depiction of transitions used for the discovery and detection of dual phosphorylation at
(A) IGFBP-1 at Ser169/Ser174 and (B) IGFBP-1 at Ser98/Ser101 sites. Colored traces
represent the detection and specificity of each transition ion. (C) Horizontal bar graphs
show relative phosphorylation levels of IGFBP-1 combined phosphorylation at Ser169 +
Ser174 and Ser98 + Ser101 dually phosphorylated peptide, as determined from total peak
intensities of transition ions from PRM MS. Bars show relative positive (green) and
negative (red) fold-change.
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3.5 Leucine deprivation induces PKCα translocation
concurrent with IGFBP-1 secretion in a time dependent
manner
As established earlier in this study, PKCα mediates both IGFBP-1
phosphorylation and secretion (Figures 6, 10 and 11). I then aimed to identify whether
PKCα is specifically activated by L0. HepG2 cells were exposed to L0 (Figure 12A) or
PKC inducer PMA (Figure 12B) in a time dependent manner (0 hrs, 6 hrs, 12 hrs) and
were differentially fractionated for enrichment of cytosolic (supernatant) and membrane
(pellet) fractions (Figure 12A-B). Western blot demonstrated time dependent PKCα
translocation to a membrane compartment (pellet) when cells were cultured under L0
(Figure 12A). At 0 hrs and 6 hrs, the expression of PKCα was relatively more prominent
in the supernatant fraction as compared to pellet fraction. PKCα membrane translocation
was induced at 12 hrs where an observed increase in PKCα in the pellet fraction and a
decrease in PKCα in the supernatant fraction (Figure 12A). Importantly, IGFBP-1
expression was highest at 12 hours of L0 exposure, concomitant with translocation of
PKCα. Treatment of cells in parallel with PMA (Figure 12B) induced PKCα membrane
translocation at 6 hrs which persisted at 12 hrs (Figure 12B), showing a similar time
course of PKCα translocation.
To obtain additional evidence for PKCα time-dependent translocation as a novel
mechanism in nutrient sensitive regulation of IGFBP-1, HepG2 cells exposed to L0 or
PMA over the same time course were used to perform IF staining for PKCα (green)
(Figure 13). PKCα translocation to membrane compartments are shown by white arrows
and occurred at 12 hrs of L0 exposure. PMA which mimicked L0 effects as detected by
western blot analysis (Figure 12B), induced a comparable degree of PKCα membrane
translocation. These data corroborate western blot findings of observable PKCα
translocation at 12 hrs of L0 exposure and 6 hrs of PMA exposure.
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Figure 12. Induction of IGFBP-1 expression is correlated with PKCα translocation.
HepG2 cells were deprived of leucine (L0) or treated with PMA in a time dependent
manner and subcellularly fractionated by differential centrifugation to yield enriched
cytosolic (S/N) and enriched membrane (pellet) fractions. (A) Western immunoblot of
fractionated time course treated L0-cultured HepG2 cells for PKCα and IGFBP-1. (B)
Western immunoblot of fractionated time course PMA treated HepG2 cells for PKCα and
IGFBP-1.
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Figure 13. Translocation of PKCα under leucine deprivation and pharmacological
activation is time dependent. Dual immunofluorescence of PKCα (green) and F-actin
stain phalloidin (red) with nuclear DAPI staining (blue) demonstrate translocation of
PKCα with L0 and PMA treatments. Arrows represent areas of high density PKCα
staining not present in the controls. Cell morphology changes with PMA treatment but
not with L0 treatment. Scale bars: 20 µm.
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3.6 IGF-1 bioactivity is altered by PKCα contributions to
IGFBP-1 phosphorylation
Cord blood plasma levels of IGF-I and IGFBP-1 are approximately 100 µg/L at
term, thus IGFBP-1 cannot bind all circulating IGF-I molecules 265. However, additional
IGFBPs act as IGF-I carrier proteins and both potentiate and inhibit IGF-I mediated
actions 151. Therefore, utilizing an IGF-1R autophosphorylation assay in P6 cells, I
combined IGF-I (25 ng) with excess IGFBP-1 (40 µg) (thereby making IGF-I limiting)
and demonstrated that changes in IGFBP-1 phosphorylation by PMA treatment (Figure
14A) and PKCα silencing (Figure 14B) affected the bioactivity of IGF-I. IGF-I binding to
the IGF-1R results in the autophosphorylation of IGF-1Rβ (Tyr1135) which is an
indicator of cell growth and proliferation 131. IGF-I alone (+IGF-I, positive control)
induced pIGF-1RTyr1135 by –1050% (p < 0.0001) opposed to the absence of IGF-I (–IGFI, negative control). Treatment with L450 and L0 media reduced pIGF-1RTyr1135 by –55%
(p = 0.0014) and –73% (p < 0.0001) against +IGF-I alone, respectively. A further –80%
decrease (p < 0.0001) in IGF-1R autophosphorylation was observed with L450+PMA
whilst L0+PMA produced a –88% decrease (p < 0.0001). Compared to L450, L0 reduced
pIGF-1RTyr1135 by –39% (p = 0.0492) while PMA reduced pIGF-1RTyr1135 by –56% (p =
0.0032). L0+PMA still produced a significant decrease in IGF-1R activation compared to
L0 (–55%, p = 0.0155). Scramble siRNA in L450 (–57%, p = 0.0004) and L0 (–75%, p <
0.0001) markedly reduced +IGF-I stimulated IGF-1RβTyr1135 phosphorylation but had
little effect on IGF-1R autophosphorylation compared to L450 and L0 treatment alone.
PKCα knockdown in L450 and L0 resulted in –44% (p = 0.0187) and –49% (p = 0.0001)
decreases in IGF-1RTyr1135 phosphorylation, respectively. Compared to scramble, PKCα
knockdown in L450 induced a +30% (p = 0.2347) increase in IGF-1R activation in L450
and a +99% (p < 0.0001) increase in IGF-1R activation in L0.
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Figure 14. PKCα mediates IGFBP-1 phosphorylation and functionally affects IGF1Rβ autophosphorylation. Representative Western blots demonstrating the effect of
equal amounts of total IGFBP-1 secreted by HepG2 cells bound with IGF-I and incubated
with P6 cells to induce IGF-1Rβ autophosphorylation. (A) Equal amounts of total
IGFBP-1 from L450, L0, L450+PMA and L0+PMA treatments. Increased abundance of
hyperphosphorylated IGFBP-1 species due to L0, PMA or combined L0+PMA
treatments significantly decreased IGF-1R activation compared with control (L450). (B)
Equal amounts of total IGFBP-1 from L450, L0, L450+PKCα siRNA and L0+PKCα
siRNA treatments. Decreased abundance of hyperphosphorylated IGFBP-1 species due to
PKCα silencing in L450 and L0 significantly increased IGF-1R activation compared with
control (L450). Equal amounts of P6 cell lysate (40 μg) were used on Western blot to
detect IGF-1Rβ (Tyr1135) autophosphorylation. Values are displayed as mean + SEM.
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*p< 0.05, **p= 0.001-0.05, ***p < 0.0001 versus control; One-way analysis of variance;
Dunnet’s Multiple Comparison Test; n=3. Significance vs +IGF-I positive control (a).
Significance vs basal control (L450:C; L450:Scr) (b). Significance vs leucine deprivation
(L0:C, L0:Scr) (c).
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3.7 PKCα expression is induced by MNR in baboon fetal
liver tissue
Next, I examined the expression of PKCα in vivo utilizing the left lobe of baboon
fetal liver from a well-established model of MNR associated with moderate FGR
199,200,202

. PKCα expression was determined by Western blot analysis of control and MNR

baboon fetal liver tissue which indicated greater expression of PKCα in MNR (+51%, p =
0.0326) at GD 120 (Figure 15A) and also at GD 165 (+27%, p = 0.0093) compared to
control (Figure 15B). These findings were consistent with qualitative IHC data with the
same tissue samples. Baboon fetal liver tissue sections also from left lobe showed more
prominent immunostaining for PKCα within the parenchyma around the central vein at
GD 120 and GD 165 (Figure 15C-F) both in MNR and control. MNR induced darker
staining within the hepatocytes of the parenchyma and around the central vein at GD 120
(Figure 15D) which remained equally increased at GD 165 (Figure 15F). These findings
demonstrate that PKCα expression is upregulated in MNR at GD 120, preceding the
development of FGR which is observable at GD 165. PKCα expression in fetal liver
remained elevated at GD 165 (term GD 185). Furthermore, these data are important in
suggesting that fetal liver PKCα is sensitive to nutrient restriction in vivo due to baboon
MNR supporting our in vitro data in HepG2 cells showing PKCα activity is nutrient
responsive.
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Figure 15. PKCα expression is increased in MNR baboon fetal liver tissue at GD 120
and GD 165. Representative western blot and quantitation for PKCα expression in
baboon fetal liver tissue at (A) GD 120 and (B) GD 165. Immunohistochemistry (IHC)
for PKCα in sectioned baboon fetal liver tissue at GD 120 (C, D) and GD 165 (E, F).
Control and MNR liver tissue sections were fixed on the same slide and immunostained
against PKCα and the nucleus counterstained with hematoxylin. All IHC images are 40x.
Scale bars are 20 µm. Values are displayed as mean + SEM. One-way analysis of
variance; Dunnet’s Multiple Comparison Test; n=19 (GD 120), n=24 (GD 165).
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4

Discussion

4.1 Key findings
Using HepG2 cells as a model for fetal hepatocytes 203,204,253,254, I report
compelling evidence of a novel mechanism of PKCα mediated phosphorylation of
IGFBP-1 in response to leucine deprivation. I demonstrate L0-dependent interactions
between PKCα, IGFBP-1, and CK2β all of which are induced by L0 and results in
IGFBP-1 phosphorylation at sites which mediate IGF-I binding (Ser101 Ser119 and
Ser169) 190. Moreover, I report a novel PKCα translocation stimulus to a membrane
compartment dependent on L0, which was mimicked by pharmacological PKC activation
and concomitantly induces IGFBP-1 expression. Using a well-established baboon model
94,97,177,201,202,259

, I demonstrate for the first time, increased greater PKCα expression in

baboon fetal liver in MNR at GD 120 prior to the development of FGR in vivo. Our data
supports a nutrient sensitive response via PKCα mediates increased fetal hepatic IGFBP1 expression and phosphorylation in FGR.

4.2 The models of nutrient deprivation
4.2.1

Utilizing leucine deprivation in vitro
Provision of the BCAAs mimics the effects of complete amino acids in protein

synthesis stimulation however, perfusion of a complete amino acid mixture except the
BCAAs has no effect on protein synthesis 266. Overall, leucine appears to be the most
potent BCAA in stimulating protein synthesis 267,268 as well as energy balance regulation
255

. In the liver, leucine does not stimulate global rates of protein synthesis however,

promotes the phosphorylation of the downstream effectors of the nutrient sensor mTOR
indicating that leucine still enhances signaling in the liver through mTOR 269,270. The fetal
liver is highly involved in regulation of fetal growth and controls the circulation of
maternal blood and nutrients 36–38,43,54,55. During fetal growth, leucine deficiencies
specifically are implicated in the development of FGR 30,58,62,65,67,72,73,84,175. Reduction in
placental transfer of leucine to fetal supply is characteristic of FGR 62,67. Downregulation
of amino acid transporter activity responsible for transplacental leucine transport in the
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placenta has been further demonstrated 30,58. The distinct effect of leucine separate from
BCAAs have been demonstrated to attenuate maternal nutrient restriction induced growth
restriction 84. The use of leucine deprivation as a cell culture model has been extensively
used in our lab to induce IGFBP-1 phosphorylation, mimicking the effects of nutrient
restriction induced FGR 94,178,191,194.

4.2.2

Utilizing MNR baboon model of FGR
I further used a well-established MNR baboon model of FGR 97,199–202 to

investigate the expression of PKCα in FGR in relation to IGFBP-1 phosphorylation.
Previous work using the same baboon model demonstrated specific FGR effects due to
30% caloric restriction, impairing placental development similar to human maternal
undernutrition 28,201. Fetal hepatic and placental IGF systems were similarly impacted in
this model compared to human FGR 97,111,201,259. The fetal liver of this MNR baboon
model of FGR previously demonstrated hyperphosphorylation of IGFBP-1, upregulation
of the AAR pathway, inhibition of mTOR and increased CK2 activity/expression
similarly to our leucine deprivation model in HepG2 cells 94,178,191.

4.3 Significance of nutrient deprivation induced IGFBP-1
hyperphosphorylation in FGR and IGF-I bioavailability
Perturbation of the IGF-axis by IGFBP-1 has been previously proposed as an
important mechanism linking limited nutrient availability to FGR 182,271. Increased
IGFBP-1 binding affinity to IGF-I occurs via IGFBP-1 phosphorylation at multiple but
discrete serine residues 181,190 which reduces IGF-I bioavailability and has been
associated with FGR 189,206,207.
IGFBP-1 phosphorylation has been demonstrated to be induced by mTOR
inhibition in hypoxia 179 and the AAR pathway in leucine deprivation 178. Systematic
mTOR inhibition targeting both mTORC1 and mTORC2 induced IGFBP-1 secretion and
phosphorylation 179. The involvement of mTOR in FGR and IGFBP-1 phosphorylation
has been well correlated in previous studies 94,177,180,272. However, Malkani et al., (2015)
demonstrated that mTOR regulates only the secretion of IGFBP-1 in leucine deprivation
and instead, the AAR pathway regulates IGFBP-1 phosphorylation. FGR is characterized
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by decreased amino acid availability which induces the AAR pathway 39,85,274. Activation
of the AAR pathway results in a kinase cascade originating with autophosphorylation of
general control nonderepressible 2 (GCN2) in the presence of uncharged tRNA
molecules which then phosphorylates eukaryotic initiation factor 2 alpha (eiF2α)
subsequently inhibiting global protein synthesis and promoting the translation of
activating transcription factor 4 (ATF4) 275–277. The AAR pathway is additionally
intimately intertwined with the mitogen activated protein kinase kinase
(MEK)/extracellular signal regulated-kinase (ERK) pathway 278. Our group evaluated the
effectors of the AAR pathway via knockdown and/or inhibition of GCN2, MEK and ERK
and determined that inhibition of any of these effectors results in decreased IGFBP-1
phosphorylation, attenuating leucine deprivation induced phosphorylation of IGFBP-1
178

. Nutrient deprivation directly induces IGFBP-1 mRNA with evidence of mTOR

directly mediating IGFBP-1 gene expression 279,280. Furthermore, we have previously
demonstrated that CK2 activity is correlated with IGFBP-1 phosphorylation in leucine
deprivation in vitro 178,191 and MNR in vivo 94,177 and that PKC activity may play a
supporting role 191.

4.4 Determining PKC interactions with IGFBP-1 and CK2 in
leucine deprivation
Previously, we demonstrated increased IGFBP-1 expression and IGFBP-1
phosphorylation, downregulated mTOR activity, upregulation of the AAR pathway and
increased CK2 activity and expression in FGR in vivo 94,177. Furthermore, we have
previously demonstrated induced mTOR+CK2β interactions in HepG2 cells in response
to hypoxia with accordant increases in IGFBP-1 phosphorylation 212. However, mTOR
does not mediate IGFBP-1 phosphorylation in leucine deprivation, thus, we proposed that
PKC may act as a nutrient responsive kinase in mediating IGFBP-1 phosphorylation 178.
In this study, we demonstrated leucine deprivation dependent co-IP of PKCα with
IGFBP-1 and PKCα with CK2β. Utilizing PRM-MS, I identified the PKCα as the leucine
deprivation dependent PKC isoform interacting with both IGFBP-1 and CK2β. I
additionally report leucine deprivation induced interactions of PKCα with IGFBP-1,
PKCα with CK2β and IGFBP-1 with CK2β via dual immunofluorescence and proximity
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ligation assay with accordant leucine deprivation induced increases in IGFBP-1
phosphorylation. I propose that PKCα instead of mTOR, mediates IGFBP-1
phosphorylation in leucine deprivation via its interactions with IGFBP-1 and CK2β
(Figure 16). Previous experimental data implicated a role for PKC in leucine deprivation
mediated IGFBP-1 phosphorylation through modulating CK2 activity 191. Consistent with
literature reports, three PKC isoforms, PKCα, PKCβ and PKCζ are reported to regulate
CK2 activity in HCT116 and HEK293 cells by directly phosphorylating CK2α at Ser194
and Ser277 281. The substrates of intracellular kinases PKC and CK2 are ordinarily
cellularly contained.213,233,282. However, IGFBP-1 is a secretory protein – likely separated
from the same intracellular compartment as PKC and CK2 – and its direct contact with
either PKC or CK2 in vivo has not been investigated. Extracellular ecto-CK2 may
phosphorylate secreted biomineralization proteins, although this seemingly occurs after
secretion of the protein; therefore, the current mechanisms as to how CK2 regulates the
phosphorylation of IGFBP-1 are unknown 283. The discovery of Fam20C as the primary
secretory protein kinase and its ability to phosphorylate IGFBP-1, albeit at sites distinct
from this study, suggests a valuable avenue for pursuing a potential bona fide IGFBP-1
kinase 218,284. Increased Fam20C activity may be necessary to produce
hyperphosphorylated IGFBP-1 species; however, regulation of Fam20C activity is not
well understood. Increased expression of Fam20A may potentiate the catalytic activity of
Fam20C which may be related to increased CK2 activity 213,285.
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Figure 16. Proposed model of the mechanistic contributions of PKCα in mediating
IGFBP-1 secretion and phosphorylation in leucine deprivation. Deprivation of the
essential amino acid, leucine, activates PKCα which interacts with CK2 and IGFBP-1
and leads to increased IGFBP-1 secretion and phosphorylation. Leucine deprivation
additionally activates the two intimately linked MAPK and AAR pathways which have
been previously demonstrated to mediate IGFBP-1 secretion and phosphorylation, in a
coordinate manner. PKCα may activate the MAPK pathway and, thus, the AAR pathway.
Solid arrows: known mechanism, large dashed arrows: putative direct mechanism, small
dashed arrows: putative, indirect mechanism.
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4.5 Identification of the PKCα isoform and its role in IGFBP1 secretion and phosphorylation
Studies on PKC in FGR are limited with little implications of the mechanisms
involved and are not applicable to FGR or particularly related to IGFBP-1
phosphorylation 239,240. PKC regulation of IGFBP-1 expression and secretion has been
established previously in HepG2 cells 221 and in human endometrial carcinoma cells 220,
but a role for PKC in IGFBP-1 phosphorylation has yet to be demonstrated prior to this
study. More than ten PKC isozymes have been identified in humans 286 thus, 239 examined
placental PKC isoform profiles in the context of placental insufficiency and demonstrated
reduced expression of “anti-apoptotic” cPKC isoforms -α, -βI and -βII while induced
expression of “pro-apoptotic” nPKC isoforms -δ and -ε 239. Specific fetal liver PKC
isoform(s) however, have not been investigated. In this study, I aimed to identify the
PKC isoform which regulates fetal growth by modulating IGFBP-1 phosphorylation.
Through PRM-MS of co-immunoprecipitation samples followed by gene
silencing, I identified PKCα as the PKC isoform which interacts with IGFBP-1 and CK2β
and demonstrated that PKCα mediates IGFBP-1 expression and phosphorylation at acidic
serine residues in response to leucine deprivation in HepG2 cells. Using conventional
inhibitor and activator approaches, I identified respective changes in IGFBP-1 at single
sites and close proximity dually phosphorylated IGFBP-1 peptides demonstrating that
PKC is positively correlated with IGFBP-1 hyperphosphorylation and that CK2 and PKC
act in concert. Using multiple approaches (co-IP, PRM-MS, IF and PLA), I provide
convincing data to demonstrate induced interactions between PKCα+IGFBP-1 and
PKCα+CK2β are consistent with increased IGFBP-1 phosphorylation and expression in
response to L0. I further characterized functional effects of PKCα mediated IGFBP-1
phosphorylation utilizing an IGF-1R autophosphorylation assay in P6 cells,
demonstrating that the IGFBP-1 phosphoisoforms generated through PKCα activation
and PKCα knockdown reduced and induced the bioactivity of IGF-I, respectively.
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4.6 Nutrient responsive activation of PKCα via translocation
Decreased nutrient availability, believed to be central to the development of FGR,
differentially affects the multiple isoforms of PKC with distinct functions in a wide
variety of biological systems 240–242,244,245. Low protein diets inhibit PKC activity,
abrogating insulin secretion in pancreatic islets 244. Amino acid deprivation in the MCF-7
breast cancer cell line induces PKCη expression 245. Leucine stimulates PKC activity in
skeletal muscle independent of mTOR and insulin, suggesting a direct nutrient sensitive
PKC response 241. Additionally, leucine also stimulated PKC activity associated with
increased mTOR and ERK activity in chicken hepatocytes 242. Functionally, PKC is
activated via phosphorylation and second messengers which mediate mechanisms such as
protein-protein interactions, subcellular targeting and PKC translocation to membrane
compartments 235. Activation of conventional PKC isoforms (cPKCs) has been reported
by conserved autophosphorylation of PKC at Thr250 287. Prior to this study, whether any
specific PKC isoform(s) played a role in fetal hepatic IGFBP-1 phosphorylation was
undetermined.
Activation of PKC isozymes are associated with its translocation from the cytosol
to a membrane compartment 231,288,289.). In our study, I used membrane fraction
enrichment and IF to demonstrate time dependent PKCα membrane translocation,
indicative of PKCα activation in response to L0 which was mimicked by PMA 289,290.
Concomitantly, IGFBP-1 expression was induced on the same time course as PKCα
translocation, linking PKCα activation to increased IGFBP-1 expression in L0. Overall,
our findings demonstrate that L0 activates and induces PKCα translocation which is
associated with increased IGFBP-1 expression and induces an interaction of PKCα with
IGFBP-1 associated with an increase in IGFBP-1 phosphorylation. Furthermore, I report
significant increases in PKCα expression prior and during the gestational dates which
physical manifestations of pathological growth restriction occur in an established MNR
baboon model of FGR 199–202. Our previous work utilizing the same baboon model
demonstrated increased IGFBP-1 expression and IGFBP-1 phosphorylation,
downregulated mTORC1/ C2 activity, upregulation of the AAR pathway and increased
CK2 activity/expression in FGR in vivo 94,177. mTOR is largely involved in FGR 180 and
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has been shown to mediate CK2 activity 177 while CK2 has been demonstrated to
phosphorylate IGFBP-1 in vitro 214,215. We have previously demonstrated induced
mTOR+CK2β interactions in HepG2 cells in response to hypoxia with accordant
increases in IGFBP-1 phosphorylation 212. In accordance to our in vitro and in vivo data
demonstrating nutrient responsive PKCα activity and expression, I propose that PKCα
instead of mTOR, mediates IGFBP-1 phosphorylation via its interactions with IGFBP-1
and CK2β in leucine deprivation and MNR.

4.7 The involvement of PKC in nutrient responsive
signaling
The models we previously used all implicate the involvement of mTOR and the
AAR as nutrient responsive signaling pathways controlling the phosphorylation of
IGFBP-1 both in vitro and in vivo 94,177–179. mTOR signaling is highly responsive to
concentration changes in leucine and essential amino acids in general 255,291,292. Our group
has characterized the involvement of mTOR inhibition in FGR via increased IGFBP-1
phosphorylation 177,180. Our data demonstrating that PKC is nutrient responsive to leucine
availability has further application to FGR pathology via mTOR. PKC functions both
upstream and downstream of mTOR in several different tissue types via integration of
nutrient related stimuli. Upstream activation of mTOR in response to hypertrophic stress,
e.g. high leucine or insulin is dependent upon coordinated activation of both PKCε and
PKCδ 293,294. Activation of mTOR via PKC is dependent upon translocation of PKC to
perinuclear endosomes adjacent to mTOR localized to perinuclear lysosomes in response
to high amino acid stimuli 295. Within FGR pathology, low nutrient stress resulting in
mTOR inhibition may be involved to coordinate PKC through a separate mechanism to
induce IGFBP-1 phosphorylation in place of coordinated activation of mTOR via PKC in
high nutrient conditions.
Amino acid deprivation activates the AAR, a separate nutrient sensitive
mechanism distinct from mTOR signaling 296,297. The AAR pathway mediating IGFBP-1
phosphorylation is dependent upon GCN2, eiF2α and MEK/ERK and AAR upregulation
is highly correlated with FGR onset 94,178,180,298. Although the MEK/ERK pathway is not
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consolidated as part of the AAR pathway, MEK/ERK is required for the translational
responses of AAR in amino acid deprivation 278. PKC is largely integrated in the
MEK/ERK pathway in several cell types. PKCα, specifically, seemingly mediates
MEK/ERK activation at several effectors. Activation of MEK/ERK by rapidly
accelerated fibrosarcoma (Raf) kinase is the classical pathway of transmitting
extracellular signals to mediate cell cycle progression and apoptosis 299. Amino acid
deprivation activates the Raf/MEK/ERK pathway via protein phosphatase 2A (PP2A) by
activating dephosphorylation of Raf at Ser259 300,301. PKCα can similarly activate the
Raf/MEK/ERK pathway in a manner independent of Raf phosphorylation at Ser259 302,
possibly through direct phosphorylation of Raf 303 or through de-activating
phosphorylation of Raf kinase inhibitory protein (RKIP) 304. Downstream of Raf, PKCα
has additionally been demonstrated to mediate growth inhibition in HepG2 cells via MEK
305,306

. In this way, PKCα may be additionally involved in activating the AAR pathway in

leucine deprivation conditions, thus contributing to IGFBP-1 phosphorylation and FGR
onset through a signaling mechanism (Figure 16).

4.8 Future directions
4.8.1 Determining direct phosphorylation of IGFBP-1 by PKC at novel
consensus sites
IGFBP-1 contains two possible phosphorylation sites (Thr50, Ser58) which
conform to the basic requirements of the PKC consensus sequence 191. Due to the
evidence of leucine deprivation induced direct interaction between PKCα and IGFBP-1,
these novel sites may be phosphorylated under leucine deprivation directly by PKCα.
Phosphorylation at these discrete sites has not been investigated and their functional
effects have not been characterized. Future studies utilizing targeted mass spectrometry to
identify whether changes in phosphorylation at these sites with PKCα inhibition or
knockdown occur is a valuable avenue to pursue. Furthermore, Thr50Ala and Ser58Ala
mutagenesis may additionally help characterize these sites effects on IGFBP-1 binding
affinity towards IGF-I or perhaps demonstrate new phosphorylation dependent effects
independent of IGF-I function.
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4.8.2 PKC regulation of CK2 and its role in IGFBP-1 phosphorylation
There is limited evidence of PKC and its interaction with CK2 within current
literature. Lee et al., (2016) demonstrated that conventional PKC isoforms -α and -β as
well as the atypical isoform -ζ directly phosphorylate CK2α at Ser194 and Ser277,
stimulating CK2α activity 307. Increased CK2 expression/activity is consistently found in
FGR models and is associated with increased IGFBP-1 phosphorylation 177,191. We have
previously demonstrated increased CK2α activation loop autophosphorylation at Tyr182
in FGR 94. In this study, my data demonstrated an interaction of PKCα with CK2β, but
not the catalytic CK2α subunit although knockdown of any CK2 subunit results in
decreased IGFBP-1 phosphorylation, implicating that the whole CK2 holoenzyme
regulates IGFBP-1 phosphorylation 177. Therefore, investigating the phosphorylation
status of CK2α at Tyr182, Ser194 and Ser277 within leucine deprivation and PMA
treatments may prove valuable in the future to demonstrate PKC mediated regulation of
CK2 activity which results in increased IGFBP-1 phosphorylation.

4.8.3 Investigating the role of PKC signaling via ERK activation
mediating IGFBP-1 phosphorylation
Nutrient responsive signal integration upstream and downstream of mTOR by
PKC 293–295 and the involvement of PKC in the AAR pathway via ERK activation
300,301,303,304,308

provides further justification for investigating possible roles for PKC in

mediating IGFBP-1 phosphorylation in FGR models. Although mTOR does not mediate
IGFBP-1 phosphorylation in leucine deprivation 178, IGFBP-1 is mediated by mTOR in
hypoxia 179. Furthermore, because PKCα specifically has been demonstrated to be
activated by leucine deprivation and regulates ERK activation at several different
upstream effectors, PKCα may play a signaling role in mediating IGFBP-1
phosphorylation indirectly through mediating the AAR pathway. Investigating potential
roles for the PKC isoforms in mediating mTOR, AAR or other nutrient sensitive
signaling pathways has thus far not been investigated and may provide additional context
as to how PKC mediates the phosphorylation of IGFBP-1.
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4.9

Limitations

The functionality IGFBP-1 phosphorylation and its inhibitory properties
pertaining to IGF-I dependent IGF-1R mediated growth is often scrutinized due to the
commonly observed lack of change in phosphorylated IGFBP-1 to total secreted IGFBP1 ratio where increased IGFBP-1 phosphorylation is observed concomitantly with
IGFBP-1 secretion resulting in an unchanged pIGFBP-1/IGFBP-1 ratio which is most
aptly outlined in Seferovic et al., (2009) 194. However, unlike other proteins which
evidence of change in functionality is dependent on phosphorylated to total protein ratios,
the functionality of IGFBP-1 phosphorylation is reflected by increased binding affinity
for IGF-I and increased IGFBP-1 phosphorylation irrespective of total IGFBP-1
secretion. This largely results in the increase of high affinity IGFBP-1 within a total pool
of IGFBP-1 which outcompetes lower affinity IGFBP-1 species at binding IGF-I. This
line of reasoning is strongly supported by the following experimental data where
proportional changes in pIGFBP-1/IGFBP-1 are not observed. First, surface plasmon
resonance-based BiaCore analysis indicated the hyperphosphorylated IGFBP-1 isoforms
found in leucine deprivation treated cells demonstrated a ~30-fold increase in binding
affinity for IGF-I 194. Second, highly phosphorylated species of IGFBP-1 produced
irrespective of pIGFBP-1/IGFBP-1 ratio is evident in our previous work using 2-D gel
electrophoresis 177. Collectively, our previous findings suggest that the predominant
increase in IGF-I affinity of IGFBP-1 is due to an increase in the abundance of specific
phospho-IGFBP-1 isoforms (site and degree of phosphorylation) rather than increases in
total IGFBP-1 or even total pIGFBP-1. Within this study, PKCα mediated changes in
IGFBP-1 phosphorylation and functionality are reflected in the IGF-1R
autophosphorylation assay (Figure 14) which uses equal amounts of total IGFBP-1 to
inhibit IGF-I function therefore demonstrating the functional effects of IGFBP-1
phosphorylation (site and degree) is independent of pIGFBP-1/total IGFBP-1 ratio.
Furthermore, confounding variables within PLA may reflect bias in our data sets
due to L0 increasing intracellular IGFBP-1 expression (Figures 7 and 9). Increased
IGFBP-1 concentration may result in the induction of PLA signals between
PKCα+IGFBP-1 and CK2β+IGFBP-1 as a result of increased total IGFBP-1 and not due
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to L0 induced interactions between two proteins. However, lack of reciprocal coimmunoprecipitation between PKCα+IGFBP-1 in L450 (Figure 3) suggests that
decreased leucine availability is necessary for an intracellular PKCα+IGFBP-1
interaction. Conversely, CK2β+IGFBP-1 reciprocally co-immunoprecipitate in both L450
and L0 (Figure 3) therefore, L0 mediated induced interactions CK2β+IGFBP-1
demonstrated by PLA may indeed be result of increased intracellular IGFBP-1 content.
The expression of PKCα or CK2β is unchanged in L0 (Figure A4), thus we do not
consider the effect of total protein concentration as a possible confounding variable for
L0 induced PKCα+CK2β interactions (Figure 8).
The cellular compartment where IGFBP-1 phosphorylation is not well
understood. Although cell fractionation into cytosolic and membrane compartments was
performed in this study to investigate the translocation of PKCα in L0 , IGFBP-1
phosphorylation was not probed for within these fractions. Further study utilizing more
robust fractionation techniques may elucidate the cell compartment or organelles where
IGFBP-1 is phosphorylated.

4.10 Overall conclusions
The aims of this study were to establish mechanistic roles for PKC in mediating
IGFBP-1 phosphorylation which is correlated to FGR. Using two models contextually
related to fetal hepatic IGFBP-1 phosphorylation: leucine deprived HepG2 cells and the
fetal liver of MNR baboons, I investigated the effects of amino acid deprivation on PKC
and the resultant effects on IGFBP-1 phosphorylation. I found that within leucine
deprivation, PKCα is the specific isoform which interacts with both IGFBP-1 and CK2β
and that these interactions were both dependent on and induced by leucine deprivation.
Furthermore, I demonstrate that PKCα is the specific isoform which mediates IGFBP-1
phosphorylation and acts in concert with CK2. PKCα knockdown mediated IGFBP-1
phosphorylation, resulting in phosphoisoforms which induced IGF-1R
autophosphorylation indicative of decreased binding affinity for IGF-I. For the first time,
PKCα is demonstrated as a nutrient sensitive kinase that translocates to a membrane
compartment in leucine deprivation. Increased expression of PKCα within FGR baboon
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fetal liver prior the physical manifestations of FGR further implicates PKCα as a key
kinase regulating FGR pathophysiology. Altogether, our data presented in this study
demonstrates new mechanisms in which IGFBP-1 phosphorylation occurs and adds to the
numerous effectors discovered to be altered in FGR such as mTOR inhibition, AAR
upregulation and CK2 upregulation. Subsequently, the implication of upregulated PKCα
activity and/or expression provides new research avenues into FGR pathophysiology
related to PKC signaling as well as direct PKC phosphorylation. Through elucidating
mechanisms underlying the pathophysiology of FGR, improvements in therapeutic
treatments which are currently lacking may result in improved prognosis in antenatal,
neonatal and adult life.
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Figure A 1. The effect of increasing PMA concentration on IGFBP-1 secretion and
phosphorylation. HepG2 cells were treated with increasing doses of PMA (0–400 nM)
to determine optimal PMA concentrations for total IGFBP-1 secretion and IGFBP-1
phosphorylation. Representative western blots of conditioned HepG2 CM indicating (A)
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total IGFBP-1 and IGFBP-1 phosphorylation at (B) Ser101, (C) Ser119 and (D) Ser169.
Values are displayed as mean + SEM.
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Figure A 2. Cell viability assay for all cell treatments. HepG2 cell viability after 24
hours of treatments with L0, Bis, PMA, TBB, scrambled siRNA and PKCα siRNA as
determined by trypan blue exclusion assay. Cell viability was determined as percentage
of measured live/total cells. All treatments demonstrated nearly identical cell viability.
Values are displayed as mean + SEM. *p< 0.05, **p= 0.001-0.05, ***p < 0.0001 versus
control; One-way analysis of variance; Dunnet’s Multiple Comparison Test; n=10.
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Figure A 3. PKCα silencing efficiency. Representative immunoblots of siRNAmediated silencing efficiency for PKCα in HepG2 cells. Cells were transfected with 80
nM PRKCA siRNA for 24 hours in serum-free media, followed by L450 or L0 treatment
for an additional 48 hours. Values are displayed as mean + SEM. *p< 0.05, **p= 0.0010.05, ***p < 0.0001 versus control; One-way analysis of variance; Dunnet’s Multiple
Comparison Test; n=3.
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Figure A 4. Effect of leucine deprivation on IGFBP-1, CK2β and PKCα expression.
Immunoblots for IGFBP-1, CK2β and PKCα in HepG2 cells cultured with and without
leucine.
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